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ABSTRACT
Interaction of beta - cyclodextrin with ampicillin, phenobarbitone ,
and phenytoin was studied and complexation was observed with all three
drugs .

Analytical methods for the quantification of these drugs were

validated.

In order to obtain an inclusion compound in the solid

powdered form, a variety of methods (freeze drying, spray drying,
kneading, and solvent evaporation) was evaluated.
freeze dry i ng was the most

Among these methods

feasible and re producible method from a

laboratory scale to a pilot scale and to the manufacturing level.
Methods using an ind ustrial model freeze drier were developed which
resulted in an increase in yield from 53% to more than 90% .

However,

because of ampicillin instability in freezing conditions, it was not
possible to obtain an inclusion compound in the solid powdered form .
Physico-chemical properties of the inclusion complexes were
evaluated by a variety of methods such as sta bility, solubility, X-ray
diffractometry, differential scanning calorimetry, infrared and proton
magnetic resonance spectroscopies, photomicrographs, etc.

The stability

of ampicillin in an acidic medium (pH 2.0) was considerably improved by
complex formation with beta-cyclodextrin. The observed apparent
pseudo-first order rate constants (hr- 1 ) of ampicillin were 1. 8 x 10- 2 ,
1. 2 x 10- 2 , and 1.1 x 10- 2 for ratios of . 1:0.0 and 1:1 . 0, 1:0.0 and 1:1 . 5
and 1:0.0 and 2.0 of ampicillin to beta-cyclodextrin, respectively.
Furthermore, it was estimated that the complex degrades nine times slower
than the drug itself, and the apparent stability constant was found to be
458.46M- 1.

Aqueous solubility of phenobarbitone and phenytoin

beta-cyclodextrin

complexes were five and eleven fold larger than that

of phenobarbitone and phenytoin alone, respectively.

A phase solubility

diagram was constructed and the apparent stability constants were
calculated for phenobarbitone and phenytoin beta-cyclodextrin complexes.
The calculated stability constants were 4.54 X 10 3M-l and 766M- l for
phenobarbitone and phenytoin complexes respectively.

Thus, the formation

and presence of the inclusion complex were confirmed by stability and
solubility analysis.

Furthermore, the proton magnetic resonance spectra

of phenobarbitone beta-cyclodextrin complex strongly indicated the
presence of the inclusion complex in the liquid phase.

The mode of

interaction and elucidation of the presence of the inclusion complex in
the solid phase were studied by X-ray diffraction, differential scanning
calorimetry, infrared spectra photomicrographs, etc .

The X-ray

diffraction spectra and differential scanning calorimetry thermograms
clearly suggested the presence of the inclusion complex in the freeze
dried material but not in the physical mixture.

The infrared spectra and

photomicrographs evaluations were such that a definitive, unambiguous
interpretation could not be made; however, they were useful to some
extent to show the interaction with beta - cyclodextrin.
A solution was prepared from the phenobarbitone beta-cyclodextrin
complex.

Unlike an official USP preparation, the solution prepared from

the complex did not require the addition of alcohol to keep the
phenobarbitone in solution.

Four months' physical and one month's

chemical stability data indicated a considerable potential especially for
pediatric use.

It was possible to prepare a pharmaceutically elegant

suspension from the phenytoin beta-cyclodextrin complex.

The suspensi on

possessed desirable qualities of a pharmaceutically elegant suspension,
such as ease of dispersion, high sedimentation volume, etc.; in addition,
the

~uspension

had a low viscosity.

Physical stability was good even in

freezing conditions and a syr ingeability study suggested a potential for
intramuscular use.
A flow study was designed using a recording flowmeter with small
quan tities of material in an attempt to predict the flow rate during
large scale operations .

The data indicated that the flowmeter was

sensitive enough that a small quantity of material could be used to
predict the flow rate, effect of form ulation and processing variables on
production scale quantities.

The flow study, and the bulk properties of

beta-cyclodextrin suggested that the material was fairly free flowing and
compressible.

The fre eze dried phenytoin beta-cyclodextrin complex

lacked flowability and compressibility; neverthless, it was possible to
compress tablets of a suitable size and weight using the wet granulation
method.

All the properties of tablets were measured and found to be

within the US P standards.

Dissolution studies in different test media

strongly suggested that the dissolution rate. for phenytoin
beta-cyclodextrin complex tablets was superior to all other phenytoin
formulations or preparations.

Furthermore, due to in situ complexation

in the dissolution medium, the dissolutio n rate of the physical mixture
of the freeze dried phenytoin and beta-cyclodextrin was found to be
similar to the dissolution rate of the freeze dried complex.
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PLAN OF THE THESIS
This manuscript is divided into seven sections, numbered in Roma n
numerals.

The sections are: I.

Results and Discussion, IV .
V.

References, VI.

Introd uction, II.

Experimental, III.

Conclusions and Suggestions for future work,

Bibliography, VII.

Appendix.

The tables and

figueres are numbered in Roman and Arabic numerals respectively .
In this thesis the tenn
is often used.

" Inclusion complex, or Inclusion com pound

The meaning of the tenn is defined on page # 10 .

The

Results and Discussion are organized into the following main sections: A.
Physico-chemical properties of complexes, B.
complexes, C.

Preparation of the

Preparation and evaluation of dosage fonns .

In some cases, the fig ures in this manuscript depict a horizonta l
dotted line.

It represents the calculated percent drug dissolved based

on the equil i brium solubility .

When experimental points are joined by

lines on figures, no mathematical relationships are implied .

All the

error bars represent standard deviation unless otherwise marked
differently in the key to the figure.
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I INTRODUCTION

A- -Historical background
The first reference to cyclodextrin was made in a publication of
"Villers in 1891 (1), who isolated a small amount of a crystalline
substance from a culture of Bacillus amylobacter, grown on a medium
containing starch. Villers named his crystalline product " Cellulosine "
because of its similarity to cellulose.

Then Schardinger (2 -4 ) observed

that Villers cellulosine often formed on starch-based culture media as a
product of putrefying microorganisms.

Schardinger succeeded in isolating

a bacillus which he named Bac illus macerans .

This is th e most frequently

used source of the enzyme glycosyl-transferase by which cyclodextrin is
now produced.
Afte r Schardinger, it was Pringsheim (5) who played the major role
in the cyclodextrin research, and he discovered the complexing power of
the cyclodextrins.

From the mid - thirties on, pure cyclodextrins were

prepared, first by Freudenberg and his co -workers, who also elucidated
th e chemical structure of cyclodextrins and discovered gamma - cyclodextrin
(6) .

The cyclodextrins, also called cycloamyloses, Schardinger dextrins,

or Cycloglycopyranoses, are cyclic oligosaccharides in which glucose
units are linked by alpha 1-4 glycosidic bonds (7,8).

French (7) in the

mid-fifties demonstrated the existence of delta and epsilon
cyclodextrins.

Thoma and Stewart (9) described further homologues

containing 11 and 12 glycopyranose units.

2

8-Properties of cyclodextrins
1. Physico-chemical properties
Since the discovery of the Schardinger dextrins, these cyclic
compounds have been of special interest as they relate to starch (7) .
However, with respect to various chemical reactions, especially their
biochemical behavior, the Schardinger dextrins vary from starch in
important aspects (7,10).

One of the rather remarkable properties of the

Schardinger dextrins is their resistance to hydrolysis by the common
starch - splitting enzymes; for example, it has been repeatedly reported
that the Schardinger dextrins are resistant to beta amylase action.
Since the Schardinger dextrins, are cyclic, there are no reducing end
groups; hence they are resistant to beta amylase attack .

The Schardinger

dextrins have been reported (11) to be stable to alpha type amylases.
Three types of cyclodextrins are most common: (a) Alpha - cyclodextrin
containing six glucose units arranged in a ring and called
alpha-Schardinger dextrin or cyclohexaamylose.

(b) Beta-cycl odextrin

containing seven glucose units and named beta-Schardinger dextrin or
cycloheptaamylose.

(c) Gamma-cyclodextrin containing eight glucose units

and named gamma - Schardinger dextrin or cyclooctaamylose.

The structure

and molecular dimensions of these cyclodextrins are shown in Figs . l and
2., and some of their more important physico-chemical properties are
given in Table I (8,12).
French and co-workers (13) found that the alpha-dextrin is
essentially completely resistant to beta amylase, the beta-dextrin is
attacked very slowly indeed and gamma-dextrin is attacked about l % as
rapidly as is starch.

So it is clear that the ring size exerts an

effect; possibly the smaller rings have greater rigidity and hence can

3

Fig . 1 Struccures of Alpha, Beta , and Gamma Cyclodextrins.
(Taken from Ref. 8).

4

Bei:a

Alpha

Gamma

~

I~
c::::::)
....

············ ··

Fig . 2 Dimensions of Alpha, Beta, and Gamma Cyclodextrins.

(Taken from Ref. 23).

5

Table I
Some physico-chemical properties of .cyclodextrins

Alpha
~-----------

~

Molecular weight
Diameter of cavity

972

- -

Beta

-

--- -

1135

1297

4.5-6.0A 0

8.0A 0

l 76A 03

346A 03

Volume of cavity

Gamma

lOAo
510A 03

Number of water molecules
taken up by cavity

6

11

17

Molecules per unit cell

4

2

6

1.85

23.2

Solubility in water gm./lOOml.
at 25°c.

14.5

6

not adapt their shape to that required by the enzyme.

Researchers are

still left with the enigma as to why ring closure exerts such a profound
effect on the starch chain.

In particular, interest has been focused on

the question as to which part of the starch structure gives rise to the
cyclic .molecules.

The cyclodextrins are not sensitive to alkalies, and

they have no well defined melting points: from 300°c on they start to
decompose. The density of cyclodextrins is l.42-l.45g/cm- 3 , solubility
data, molecular weight, cavity diameter, etc. are given in Table I.

The

cyclodextrins are white crystalline powders, very stable, slightly sweet
in taste, and they are more resistant to hydrolysis than the linear
dextrins (8).

There are no reported data available in the literature

with respect to flow and compression characteristics of cyclodextrins
(Some of these properties are the subject of this study).
In solution, the cyclodextrin's cavity cannot be regarded as an
empty space. For example, the diameter of the cavity in
alpha-cyclodextrin is 4.5A 0 and its height is 6.7A 0 and therefore the
total volume is 64ml/mole.

The energy required to maintain an empty

space of this dimension would be approximately 40kcal/mole.

This value

is so high that it is hardly conceivable that the cavity could remain
empty (8).

The other two cyclodextrins (beta and gamma), having a larger

diameter, this 'energy requirement is even higher.

The viscosity of

aqueous cyclodextrin solutions differs only insignificantly from that of
water (14).

One of the most striking properties of cyclodextrins is

their ability to form inclusion complexes (8,15).
dicussed in detail separately.

This property will be

2. Cyclodextrin metabolism and toxicity
Detailed studies of metabolism and toxicity are necessary for any
compound intended for use in pharmaceuticals or in food.

Therefore,

utilization of the cyclodextrins in the pharmaceutical or food industries
depends to a large extent on knowledge of the effects they have on living
organisms.

In 1963 it was discovered that, in rats, 14C - labeled alpha

and beta cyclodextrins are distributed into tissues and organs similarly
to 14C-labeled starch (10) .

It is remarkable that, on feeding

14C-starch, the 14C-level of the 14C0 2 expired reached a maximum after
one hour; whereas, in the case of 14C-beta cyclodextrin, the maximum
appeared after approximately nine- hours.

The total quantity of expired

14C0 when related to the carbbohydrate consumed, was about equal in both
2
experients. The cyclodextrins are not metabolized as rapidly as starch;
this is because they are cleaved more slowly than linear dextrins (10),
and are not hydrolyzed by enzymes which attack terminal groups.
Szejtli et al. (16), reported a study in which they fed rats with
beta-cyclodextrin and glucose, both uniformly labeled with 14C, and
measured the radioactivity level of blood and exhaled air.

With glucose,

about 2 % of the initial radioactivity was found to be present in blood
within 10-min. With labeled beta-cyclodextrin, only 0.5 % of the initial
radioactivity could be recovered from blood and this value was reached
only between the 4th and 10th hour following administration .

The amount

of exhaled radioactivity was practically identical with rats treated
orally with 14C -glucose or
period.

14C~beta

cyclodextrin and followed for a 24- hr

No significant difference was found in the tissue distribution

of radioactivity (17 ) .

Further studies (15,16) indicated that beta

cyclodextrin is metabolized and that the intestinal flora are probably
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responsible for the first step in the degradation of cyclodextrin.
Attempts to detect the intact beta-cyclodextrin

by high performance

liquid chromatography) in blood following oral administration of
14C-labeled substance gave negative results; no significant radioactivity
was found at retention times that correspond to the beta-cyclodextrin.
Chronic six months oral toxicity of the beta-cyclodextrin was
studied with doses up to l.6gm./body weight kg. / day in rats, and up to
0.6gm . /body weight kg./day in dogs (18).

No toxic effects were observed

with respect to weight gain, food consumption, or biochemical values of
clinical significance.

Pathologic and histopathologic investigations

following the six-month treatment did not reveal any sign of toxicity in
the digestive organs, central nervous system, cardiovascular system, or
in any other organ tested.

In addition, the beta-cyclodextrin was also

devoid of embryotoxic effect.

Chromosomal tests performed in rats

treated for six months did not reveal increased incidence of spontaneous
abberrations or gene mutation (18). The cyclodextrins administered in
high doses (above SOmg./body weight kg . ) subcutaneously,
intraperitoneally, or intravenously, can induce renal damage in the rat,
but at lower doses the compound can be administered without ill effects
( 20,21).
All toxicity tests have shown that the orally administered
cyclodextrin is innocuous.

According to the report (22) of the ·Food and

Agriculture Organization (FAD), enzjmatically modified starch-- this
includes cyclodextrins-- is also · toxicologically harmless.

The FAQ

report concludes that there is no need to conduct a toxicological
examination in the case of enzjlllatically modified starch products.
However, considering the reduced activity of starch-degrading enzjmes
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towards cyclodextrins, and also their retarded resorption and slow
metabolism when administered orally, it is the author's opinion that
additional toxicological studies of cyclodextrins seem nevertheless to be
justified, especially if the parenteral route of administration were to
be used.
3. Cyclodextrin derivatives
Among the natural cyclodextrins, beta-cyclodextrin is widely used in
many fields because of its cavity size (8 .0 A0 }, and the ease with which
it can be obtained at a relatively low cost on a large scale (8,15,23) .
The present cost of this material is about $ 500 per kilogram.
derivatives of cyclodextrins have already been reported (8) .

Numerous
However,

for biomedical applications only a small number of cyclodextrin
derivatives have been tested (24).
Recently, the chemically modified cyclodextrins have received
considerable attention because their physico-chemical properties are
different from those of the natural cyclodextrins (25) .

Among the

properties that can be modified are solubility, membrane permeability,
chemical reactivity, and dissociation constant (26).

These properties

will provide a rational basis for the design of formulations, and a means
of improving the efficiency of drug activity; however, it should also be
noted that modified cyclodextrins cause more hemolysis and local tissue
damage than do natural cyclodextrins (27) .

Hence, the practical

application of modified cyclodextrins must await the results of
exhaustive toxicological studies.
C-lnclusion complexes
For a half century chemists speculated that certain molecular
structures might enclose other structures of suitable size and geometry.
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It was not until late 1940's that this fonn of molecular architecture was
actually shown to exist.

Then, as so often happens, when the time is

ripe, the discovery was made almost simultaneously by several research
groups (15,28-33).

The tenn " Einschlussverbindung " (i nclusion

compound) was introduced by Schlenk (33) .

Schlenk defines inclusion

compounds as addition compounds in which one entity fits into and is
surrounded by the crystal lattice of the other.

These inclusion

compounds may be called" no bond" complexes and are characterized by
the lack of adhesive forces between the components of the complex.

It is

not a chemical interaction which is the primary force which causes an
inclusion compound to fonn, although this may be a factor in the net
complexation observed .

There are some other names for inclusion

compounds used in the literature, such as, abduct, clathrate, molecular
compound, complex, etc.

Inclusion complexes are known in six different

fonns (34), depending on the architecture of the " host " structures and
the shapes of the cavities they enclose (Fig. 3) .
arrangements that allow this snug

11

hand in glove

The structural
11

or

11

lock and key"

fitting of molecular shapes differ from one family of inclusion compounds
to another (34).

In any event, according to John F. Brown Jr . (34), the

discovery and detaiJed understanding of inclusion compounds have provided
a powerful support for the hypothesis that such " hand in glove " or
" lock and key

11

structures ca n indeed account for biochemical

specificity, and hence that inclusion structures play a central role in
the functioning of living orga nisms.
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Key:

a- Spherical complex : b - Canal complex : c- Layer complex
d-

Six differenc forms of in clusi o n complexes.

~olecular

sieve complex: e- Hol low s pace complex: and

f- Cylindrical complex.(Taken from Ref. 34).
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1. Steric requirements
The steric configurations of the molecules are such that the
" host " molecule can spatially enclose the " guest " molecule, leaving
unaffected the bonding systems of the components.

This type of fonnation

is typified by the Schardinger dextrins or cyclodextrins (35).

According

to Cohen and Lach (36), geometrical rather than chemical factors are
decisive in detennining the kind of guest molecules which can penetrate
into the cyclodextrin cavity to fonn an inclusion complex.

The extent of

the complex fonnation also depends on the polarity of the guest molecule.
Because of the cyclodextrins' cyclic structures and relatively large open
space within each molecule ( 6.0 A0 for alpha, 8.0 A0 for beta, and
10.0-11 . 0 A0 for gamma ) , they have been reported to fonn complexes with
different sized molecules (36) .

For example, naphthalene is too bulky

for alpha-cyclodextrin, and anthracene fits only into gamma - cyclodextrin.
On the other hand, propionic acid fits well with alpha-c yclodextrin , but
it is too small to fit properly in larger cavitives. Similarly the role
of molecular dimensions is well demonstrated by the complex fonnation
with halogenated benzenes (28) .

Reaction of the cyclodextrins with

halobenzenes show that 1:1 complexes may be prepared from chloro, bromo,
and iodobenzenes.

Chlorobenzene reacts only with alpha-cycl odextrin ,

brompbenzene reacts with alpha and beta-cyclodextrins, and iodobenzene
reacts with beta and gamma-cyclodextrins.

According to Va n Hooidonk and

Breebaart-Hansen (37), the diameter of the cavity in beta-cyclodextrin is
about 8.0A 0 and the size of the benzene ring is about 6.8 A0 ; therefore a
substituted benzene ring can penetrate into the ring. Certain chemical
groups or substituents may promote complex fonnation or stability.
However, the stability of the complex is proportional to the hydrophobic
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characater of the substituents.

Thus, a methyl, ethyl, or phenyl

substituent will increase the complex formation or stability.

A methyl

group in the ortho position to a carbonyl group has a shielding effect on
the hydrophilic carbonyl group, thereby increasing the hydrophobicity of
the whole molecule.

A similar

relatively weak effect.

substitu~nt

in the para position has a

Hydroxyl groups hinder complex formation, but

their hydrophilic effects decrease in the order ortho, meta, and

para

(38).

2. Complexation by cyclodextrins
Many drugs are amenable to inclusion complex formation (36 ,39-43 )
with cyclodextrins.

As shown in Fig. 1, the lining of the cyclodextrins

cavity is formed by hydrogen and glucosidic oxygen atoms.
this surface is rather apolar (8).

Therefore,

In aqueous solution the apolar

cyclodextrin cavity is occupied by water molecules that are in an
energetically unfavored state

polar- apolar repulsion ) and are,

therefore readily replaced by an appropriate • guest molecule • that is
less polar than water.

Schematic illustration of the complexation

process is as shown in the Fig. 4 (8).

The

small circles represent

water molecules, the large ones represent cyclodextrin rings.

The outer

surface of the cyclodextrin ring is hydrated, but the water molecules in
the ring cavity are in an energetically unfavorable condition because of
the nonpolar surface of the cavity.

The hydrophobic part of the

potential guest molecule is highly hydrated, while the nonpolar aromatic
ring repu 1ses the water mo 1ecu1 es.

The result of the comp 1ex formation

is that the nonpolar part of the guest molecule penetrates into the
nonpolar cavity, thereby establishing an energetically favorable
nonpolar-nonpolar interaction, while the protrudi ng hydrophilic part of

14

Fig. 4:

Schematic representation of the formation of
cyclodextrin inclusio n complexes.(Taken from Ref. 23).
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the guest molecule outside retains its hydrated shell.

Among the various

changes (44) that occur upon complexation with cyclodextrins the
following may be of considerable advantage:
a. Or ganoleptic properties
b. Conversion of a liquid drug to a solid fonn
c. Physico-chemical properties
d. Content unifonnity
e. Dissolution
f. Bioavailability
g. Target organ oriented dosage fonns
D-Preparation of the inclusion complexes
The method of preparation of inclusion complexes depends on the
properties of the guest components (8 ,15 ).

The most common procedure is

to stir or shake an aqueous solution of cyclodextrin (cold or wann) with
the guest molecule or its solution.

Equilibrium is reached with intense

stirring and slow cooling in a few hours.

The guest molecule content

cannot be increased by repeating the heating and cooling steps .

After

having attained the equilibrium, water can be removed by any one of the
. fa 11 owing methods.

1. Solvent evaporation
Equimolar quantities or up to a ten - fold excess of water soluble
substances are dissolved in concentrated wann or cold aqueous solutions
of the cyclodextrins.

The inclusion compounds crystallize out on slow

cooling or eva porati on (45).
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2. Kneading
In this case the cyclodextrin is not dissolved, it is kneaded with a
small amount of water to make a slurry and then guest components are
added to the slurry of the cyclodextrin.

On stirring in a mixer, the

viscosity of the mixture increases, giving a paste which can be dried and
powered.
3. Freeze drying and Spray drying
These two methods are suitable when fine particles of the complexes
are desired.

Equimolar quantities of host and guest molecules are

dissolved in a saturated solution of the cyclodextrins.

Substances wh i ch

are not water-soluble can sometimes be dissolved by adding an appropriate
amount of 28% ammonium hydroxide solution.

The solution are then either

freeze dried or spray dried (8) .
E-Methods of inve sti gating the complexes
1. Solubility

There are many examples which demonstrate the effect of
cyclodextrins on the solubility of substances that are sparingly soluble
in water (39 -43).

The solubility of the guest component increases

linearly with the amount of cyclodextrin added.

According to the method

of Higuchi and his co-workers (46,47) the stability constant and
stoichiometry can be detennined from the phase s_olubil ity diagram .

The

phase solubility diagram can be constructed by plotting the total molar
concentration of substrate as a function of the total molar concentration
of ligand.

The ascending linear part of a solubility diagram (Fig.5,A )

is generally ascribed to the fonnation of a 1:1 complex and the stability
constant can be calculated as follows.
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K = Slope I S0 (1 - Slope)

Eq.

(1)

Where S is the equilibrium constant of the substrate S, in the
0

absence of the ligand L, and thus S0 is equal to the intercept of the
plot in Fig. 5,A.

In some cases, the phase solubility diagram shows a

plateau region before the descending part of the curve (Fig.5,B), making
it possible, on the basis of the length of the plateau, to estimate the
stoichiometry.

In such plots, the fonnation of the 1:2 com ple x is

assumed and the stability constant can be calculated by using Eq. 1 and 2
according to (45,46) as follows:

Eq.

(2)

Where Lt is the total ligand concentration and St is the equilibrium
solubility of the substrate in the presence of ligand.
2. Diffusion
Gas diffusion provides one of the most direct demonstrations of
random molecular motion. Without this phenomenon, the perfume industry
would not exist, and skunks would be much less feared.

The diffusion

properties of cyclodextrin complexes as reported in the literature (8 ,48 )
have been used to investigate the complex fonnation by cyclodextrins.
For example, when indomethacin solution was separated by a semipenneable
membrane from a buffer solution, a 1:1 equilibrium was observed (47).
Whereas, when the indomethacin solution was separated by a semipenneable
membrane from a buffer solution saturated with beta-cyclodextrin a higher
concentration of indomethacin was observed on the side containing
cyclodextrin, because, the diffusion rate of the complex was slower due
to the increase in molecular weight and extensive hydration of
beta-cyclodextrin.

Thus, the concentration of indomethacin was higher on
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the side containing cyclodextrin, indicating that the majority of the
indomethacin molecules were fanned in a complex.
3. X-ray spectroscopy
Takeo and Kuge (4g,5Q) published X-ray diffraction diagrams of
several alpha, beta, and gamma cyclodextrins complexes.

According to

their studies, inclusion complexes can be detected quickly and directly
by X-ray diffraction.

If the diffraction pattern does not correspond to

those of pure components, a true inclusion complex may exist.

In the

case of liquid guest molecules X-ray powder diffraction is the most
useful method fo r the detection of inclusion complex fonnation .

Since

the liquid guest molecules produce no diffraction pattern at all, if the
diffractogram differs significantly from that of uncomplexed
cyclodextrin, fonnation of a crystal lattice of a new type and complex
fonnation can be established. Single X-ra y structure analysis is the best
method for detecting complex fonnation (15) .
4. Infrared (IR) spectroscopy
The complex fonnation may be proved by IR spectroscopy, the
characteristic bands of cyclodextrin, which represent the overwhelming
part of the complex, are influenced by complex fonnation .

Bands due to

the included part of the guest molecule are generally shifted or their
intensities are altered (51).
5. Differential scanning calorimetry (DSC)
In certain cases cyclodextrins complex fonnation can be proved by
DSC. Kurozumi

~

(51) have found that freeze dried mefenamic acid

gives at 232°c an endothennic peak; its mechanical mixture with freeze
dried beta cyclodextrin gives the same peak at the same temperature .
the beta cyclodextrin complex prepared by freeze drying or

But
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crystallization from water does not give any peak .

This behavior is

usually characteristic of the inclusion complexes.
6. Proton magnetic resonance (PMR ) spectroscopy
Demarco and Thakkar (52) investigated cyclodextrin inclusion complex
formation by PMR spectrometry.

In their study, they observed that the

beta-cyclodextrin spectrum was shifted upfield in the presence of guest
molecules.

According to Demarco and Thakkar, if the guest molecule is

accommodated in the cyclodextrin cavity, then the hydrogen atoms located
in the interior of the cavity (C-3-H and C-5-H) will be considerably
shielded by the guest and hence the signal will be shifted upfield.
Whereas, the hydrogen atoms on the outer surface (C -2- H, C-4- H, and
C-6-H) will not be affected by the guest molecule, hence the signals of
those protons will remain unchanged.

The cyclodextrins contain six,

seven, and eight units of glucose, and due to the multiplicity of (C -3 - H
and C-5 - H) protons located in the interior of the cavity, an exact
evaluation was impossible.
7. Other methods
Inclusion of a guest molecule can also be investigated by monitoring
changes in its cond uctivity {53- 55), apparent changes in its basicity
(56,57), changes in the optical spectra, thermodynamic parameters, etc.
(8,58).
F-Present and possible future potential of cyclodextrins in
pharmaceutical products.
1. Organoleptic properties
It is possible to improve the organoleptic properties of drug
molecules by inclusion complexation with cyclodextrins (8,15,59,60).
instance, femoxetine is a selective serotonin uptake inhibitor with

For
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antidepressant properties (59}.

This compound is used as a water soluble

salt, but it has a very bitter taste which hinders the development of
oral liquid formulations.

A study was undertaken to obtain a liquid

formulation of femoxetine with acceptable oraganoleptic properties
through inclusion complexation with the beta -cyclodextrin (59}, and the
results were favorable.
2. Conversion of a liquid drug to a solid form
Liquid compounds can be converted into the solid form by inclusion
complexation with cyclodextrins (61).

Organic nitrates have been used

for a long time for the treatment of angina pectoris, and they are still
widely used.

For example, one of the best known drugs is

nitroglycerin,which is a highly explosive liquid drug and therefore
cannot be tabletted.

However, by complexation with cyclodextrin, it is

possible to convert the drug into solid form and tablets can be
manufactured (61).

In addition, complexes of unsaturated fatty acids,

ascaridol, clofibrate, methyl pentynol, etc . , have been converted into a
solid form by complexation with cyclodextrins (62,63).

These reports

suggest that the product obtained in this way can be used to man ufacture
t ablets.
3. Physico-chemical stability
Inclusion complexation can be regarded as micro-encapsulation,
because each guest molecule is surrounded by cyclodextrin molecules and
is thus, from the microscopical point of view, encapsulated.

This

phenomenon can be exploited by industries which manufacture drugs,
foodstuffs, plant protective agents, etc.

The use of cyclodextrin

complexes in indust r ies, particularly in the pharmaceutical field, can
result in the following improvements in stability.

22
a. Stabilization of light or oxygen sensitive substances
The extremely labile vitamin 03 (c holecalciferol) should be
mentioned here; heat, light, and oxygen all increase the degradation of
vitamin 03 by oxidation, but these effects can be inhibited by the
inclusion complexation (64 ,65 ).

Similarly, inclusion of vitamin A in

alpha-cyclodextrin increased its stability against heat (66).

The

sensitivity to light of clofibrate (67) and guaiazulene (68) are reduced
by the inclusion complexation with the cyclodextrins.
b. Modification of the chemical activity or stability of guest molecules
Lach and Chin (41) have reported that the alkaline hydrolysis of
benzocaine becomes considerably slower in the presence of
beta-cyclodextrin.

In 1 % beta-cyclodextrin solution the half- life of

benzocaine is increased five-fold . Chin, Chung, and Lach (69) studied in
detail the alkaine hydrolysis of esters of various aminobenzoic acids and
acetylsalicylic acid.
It was found that the rate of hydrolysis decreased when in clusion
was complete.

If, however, incorporation of the guest molecule was

incomplete then the hydrolysis rate increased.

Since the inclusion was

complete, the rate of hydrolysis of para, meta, and ortho aminobenzoates
was decreased by the beta-cyclodextrin.

Beta-cyclodextrin has also been

shown to have a stabilizing influence on procaine, atropine, aspirin, and
phenylbutazone (70) .

Indomethacin is stabilized by beta-cyclodextrin but

not by alpha-cyclodextrin (71) .

In addition, there are many reports on

the modification of the chemical activity or stability of guest molecules
by inclusion complexation with the cyclodextrins (8 ,15, 72,73).
c. Fixation of very volatile substances
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A reduction in the volatility can be demonstrated by an increase in
the boiling point of both liquids and solids that sublime.

Uekama et al.

(67) demonstrated the reduction in volatility of drugs forming inclusion
complexes by differential thermal analysis and thermogravimetry. They
used this technique to show the reduced volatility of the clofibrate
beta-cyclodextria complex. The differential thermal analysis of
clofibrate gave an endothermic peak around 150°C corresponding to the
boiling point. This endothermic peak disappeared with the formation of an
inclusion complex . Fu r thermore, the thermogravimetry curves showed
significant reduction in the volatility of clofibrate as a result of
complex formation.

Uekama~(74)

obtained similar results with the

complexes of derivatives of cinnamic acid and

beta - cyclodextrin, and the

complexes of benzaldehyde and alpha, beta, and gamma-cyclodextrins (75).
Szejtli~

(76) produced

beta -cyclodextrin complexes of 25 different

aromatic substances, and the solid complexes obtained enabled better
handling of the pr oducts . They contained all the constituents of the
original substa nc es.

Nakai~

(77) used the thermogravimetry method

to study the volatility of the physical mixtures, the ground mixtures,
and the inclusion complexes of parahydroxybenzoic acid with the alpha and
beta-cyclodextrins. The sublimation of parabydroxy benzoic acid was
considerably reduced by the inclusion complex. The inclusion complex with
alpha - cyclodextrin showed the greatest reduction of sublimation, most
probably due to a more tight fit within the cavity of alpha-cyclodextrin
molecule .
4. Content uniformity
This United States Pharmacopeia (USP) content uniformity test is
designed to establish the dose equivalency of solid dosage forms. The
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content unifonnity of a solid dosage fonn cannot be better than that of
the granulation of those dosage fonns. There are three possible factors
inherent in the tablet manufacturing process which may cause difficulties
in achieving a good content unifonnity namely: (a) nonunifonn
distribution of drug throughout the powder mixture or granulation, (b )
segregation of the powder mixture or granulation during the manufacturing
process, and (c) tablet weight variation . These three fact ors may cause
more diffculties in achieving a good content unifonnity with potent
low-dose drugs (oral contraceptives, etc.). It is not difficult to
comprehend why a perfect physical mixture never occurs or why the
segregation occurs with powder mixtures intended for direct compression
or why with wet granulations drug migration is likely . Some or all of
these problems may be alleviated by complexation with cyclodextrins.

If

a drug gives a stable complex, then the crucial question is the required
dose. In addition to the required dose (active ingredient ) , tablets
contain a number of inert materials.

These include diluents, binders,

distintegrants, and lubricants. If the required dose is 50mg or more it
may not be difficult to distribute the active ingredient unifonnly in the
inert materials to compress a tablet with suitable weight.

However, if

the required dose is a few milligrams or less, it is very difficult, if
not impossible, to achieve a good content unifonnity, since more than 90%
of the tablet weight is filled with the inert materials .
By the inclusion complexation technique, a drug can be dispersed at
a molecular level, and usually the drug content in the inclusion complex
is in the range of 15- 25% (8). If the required dose is a few milligrams
or less then it may not be difficult to disperse unifonnly lOOmg of the
complex instead of 15 or 25mg of drug into the inert materials. By this
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type of molecular dispersion it is conceivable that some or part of the
previously mentioned factors may be reduced in achieving a good content
unifonnity of potent low dose drugs.
5. Dissolution
The number of papers and patents describing drug -cyclodextrin
complexes, their stability, dissolution rate, bioavailability, and
phannacological effects has been growing rapidly in phannaceutical
research (8,15,23). Solubility changes have been observed as a function
of complexatio n and substantial increases in drug stability have also
been reported (78,84) . These reports

als~

showed that the improved

aqueous solubility by complexation resulted in an enhancement of the
dissolution rate of various drugs (78,84}. The dissolution - absorption
process of an orally administered drug can be approximated by the
following simple kinetic model.
D

Kd

GI

~~~~~-

Kr

B

Eq.

(3)

-~~~~~-

Where D is the oral dose of the drug, GI is the concentration of drug
dissolved in the gastrointestinal tract, B is the concentration of drug
in blood; Kd represents the rate constant of dissoltuion, and Kr
represents the rate constant of absorption .
When Kd .( Kr, then the dissolution is the rate detennining step in
the drug absorption .

In such cases Kd may be increased by complexing

with cyclodextrins. For example, the dissolution rate of proscillaridin
complexes was much greater than that of proscillaridin itself (85}.
Interaction of digitalis glycosides with cyclodextrins has been reported
(86). It has been clearly shown that the dissolution rate (in acidic
medium) of the complexed fonn of digoxin is about 100- fold more than that
of digoxin itself. In addition, during the dissolution experiments, the
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simultaneous conversions of digoxin to hydrolysis products were also
follwed by HPLC. The rapid dissolving form of the complex showed the
reduced decomposition compared to that of digoxin alone. The dissoltuion
of menadion (vitamin k3 ), and its beta-cyclodextrin complex in water was
found to be increased by 10 to 12- fold (23). Improved dissolution
characteristics of acetohexamide has been reported by complexation with
cyclodextrins (87). Similarly, there are many examples which clearl y
demonstrate that complexation with cyclodextrins has improved aqueous
solubility ( 78-84 ) and dissolution rate of various drugs
(8,71,74,88,89) .
Dissolution tests have two possible uses. They may, as indicated in
the above discussion, be predictive of the rate and extent of drug
entering a patient's blood stream . However, a quantitative relationship
between dissolution and bioavailability can not be assumed for any given
drug; such a relationship is not necessarily simple . Secondly,
dissolution tests have value as a method of controlling batch to batch
variation. USP XX requires dissolution tests for virtually all
conventional solid oral dosage forms. Thus to some extent dissolution has
become an end itself.
6. Bioavailability
Bioavailability of a drug product is defined as the rate and extent
of absorption. Biological availability is determined by comparing blood
levels produced by a test product with those produced by an intravenous
injection, an aqueous solution, and a commercial dosage form of the drug.
When making comparisions of the biological availability of products,
normally the following three parameters are determined.
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a. Maximum plasma concentration
b. Time to reach maximum plasma concentration
c. Area under the curve
Whenever a drug is administered by the oral route, there is a
possibility that part of the dose may not reach the blood due to
incomplete absorption (90 ,91 ). This result may arise for a variety of
reasons, such as poor dissolution of the drug in the gastrointestinal
fluids (92-95), first-pass liver metabolism (90) , etc. In instances where
bioavailability is incomplete, the ratio of oral to intravenous blood
level curve areas is less than unity (96). Hence, a great deal of
investigation is required to appreciate fully the role of the
gastrointestinal tract in drug absorption. For example, a thorough
investigation is required with respect to interactions of drug with
dietary factors, physiological and physico- chemical factors (97) , etc.
In this section, enhancement of bioavailability by cyclodextrin inclusion
complexation is discussed. Improving the absorption of drugs may be one
of the important practical applications of cyclodextrin complexes.
Following the oral administration of the drug, practically no
cyclodextrin is absorbed (23) . Cyclodextrin is onl y a carrier agent; it
transports the lipophilic guest molecule through an aqueous milieu to the
lipophilic membrane of cells in the gastrointestinal tract. There the
guest molecule is absorbed, since the membrane has a higher affinity for
a lipophilic guest molecule than the cyclodextrin itself (23). The
relationship of complexation to the absorption and distribution of a drug
in the body is well documented in the literature (98).
The dissociation and association reactions of cyclodextrin complexes
in solution are very rapid, and the equilibrium of free and complexed
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drug is established instantaneously (23,99). This may perhaps be used to
improve medication through the use of tablets containing both the
hydrophobic drug complexed to cyclodextrin and the same drug in the free
form. The former would enter the circulation very rapidly, while
dissolution of the. latter would occur slowly and form a drug depot (100).
Andersen, F.M., et al. (59), reported the absorption of femoxetine
(a selective serotonin uptake inhibitor with antidepressant properties )
in five human volunteers.

In this study, five subjects were given six

sugar-coated tablets each containing lOOmg of femoxetine salt and
femoxetine beta-cyclodextrin complex formulated as a suspension.
dose of the suspension was equivalent to 600mg femoxetine salt.
study was single dose and cross -over design.

The
The

Each volunteer was given

the doses with an interval of at least two weeks between each
administration.

The blood level was determined by gas chromatography.

The area under the blood level curve (AUC) was calculated using the
trapezoidal rule. The AUC for the cyclodextrin complex varied from 23 to
96 ng"h"kg"m1- 1 ·mg- 1 , while the corresponding values were 30 to 120
ng"h"kg"m1- 1 ·mg-l for the sugar-coated tablet.

There was statistically

no difference between the AUCs for the two formulations.
plasma concentration was reached within one to four hours.
variations were similar to those observed in AUCs .

The maximum
The

In conclusion, the

bioavailability of femoxentine beta-cyclodextrin complex, formulated as a
suspension, was found to be similar to that observed from a sugar -coated
tablet of femoxetine salt.

However, this study would have been more

meaningful if the results of the above study had been compared with (a )
femoxetine tablet, preferably the uncoated tablet, or {b) with the same
dosage form.
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In vivo absorption studies were undertaken to find if the in vitro
dissolution enhancement of digoxin from its cyclodextrin complex
increases in the absorption of the drug (86).

In this study, digoxin

tablets containing 100/ug digoxin and its gamma -cyclodextrin complex
containing 100/ug digoxin were administered orally to six dogs.

The

concentration of digoxin in the plasma sample was determined by enzyme
immunoassay.

The maximum plasma concentration of 0. 90

minutes was obtained.

~

0. 14mg/l at 45

This concentration level was three times higher

than that of digoxin alone.

The area under the plasma concentrati on time

curve of th e complex up to 24 hours was found to be 5. 4 times as much as
that of digoxin alone.

In addition, the area under the curve of the

complex containing 50/ug of digoxin was found to be superior to that of
100/ug digoxin alone.

Thus, the improved bioavailability of digoxin by

gamma-cyclodextrin complexation suggests a decrease in doses and fewer
side effects in oral digitalis glycoside therapy.
Ukema, K.,

~-

(87), studied the hypoglycemic action of

acetohexamide-beta-cyclodextrin complex with that of acetohexamide by
oral administration in five male rabbits .

The complex equivalent to

30mg/kg of acetohexamide was administered as a suspension in 80ml of
water.

In each case at least seven days were allowed between each blood

glucose estimation.

The reduction in the blood glucose level was

obse rved in the system co ntain ing the complex.

When results were

compared using paired Student's t-test, the difference was found to be
statistically significant .

However, it is the opinion of the author of

this thesis that, a detailed study should be made to elucidate the
absorption mechanism of cyclodextrin complex .
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Seo, H. , et al. (88), studied in vivo absorption of spironolactone
(S P) to determine whether or not the enhanced in vitro dissolution of SP
from its beta or gamma - cyclodextrin complex increased the GI absorption
of the drug.

SP is a steroidal aldosterone antagonist that is widely

used fn the treatment of hypertension, edematous states, etc.

Because of

its low solubility in water, the bioavailability of the SP preparation is
known to vary significantly among brands and batches (a uthors reported
with proper references).

In the above study, four male beagle dogs were

administered orally a capsule containing (5mg/kg of body weight as SP),
the drug, and its complex.

The administration sequence was based on a

crossover design with an interval of more than one week.

The plasma

concentration was determined by high pressure liquid chromatography.
standard curve range was from 20 to 200ng/ml.

The

The beta and

gamma-cyclodextrin complexes produced a maximum plasma concentration of
103_: 28"3ng/ml and 131.!_14 "7ng/ml. at 90-minutes, respectively .

These

concentrations were about two to three times higher than that of SP
alone.

Similarly, the areas under the curves of complexes up to 24 hours

were found to be more than two times greater than SP alone.

The authors

did not report any significant difference in time to reach the maximum
concentration (Tmaxl·

It is the authors' opinion of the above study

that the enhanced bioavailability of SP produced by beta or
gamma-cyclodextrin complexation makes possible the use of a lower dose
with fewer side effects in (o ral ) SP therapy .
Tsuruoka, M., et al. (9 5) , studied the absorption of freeze dried
phenytoin, phenytoin and its beta - cyclodextrin complex in a group of four
female beagle dogs.

Dogs were given orally 300mg of phenytoin and its

complex equivalent to 300mg phenytoin.

The concentration of phenytoin
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was detennined by gas chromatography.

There was a twofold increase in

the area under the curve of the blood level.

Further, it was reported in

this study that increased bioavailability of phenytoin by means of
beta-cyclodextrin complexation suggested the possibility of smaller doses
and fewer side effects in phenytoin therapy.

The details of the studies

such as, statistical evaluations, etc., were not clearly reported.
Indomethacin and its beta - cyclodextrin complex were administered
orally to rats (100).

The rats were treated orally with 30mg/kg

indomethacin and its complex equivalent to 30mg of indomethacin.
Indomethacin level in the blood was measured by high pressure liquid
chromatography.
after treatment .
complex.

The maximum blood level was found between 1 and 4 hours
It was approximately 25% higher in the case of the

The details of the experimental design, such as number of

animals, statistical evaluations, sensitivity of the assay method, etc.,
were not reported; however, based on the reported data it appears that
the beta-cyclodextrin complex may be used to increase the bioavailability
of indomethacin.
Tokumara, T., et al. (101), studied the bioavailability of
cinnarizine with beta-cyclodextrin in three male beagle dogs.

Two

tablets of cinnarizine and its complex containing 2Smg of cinnarizine in
each tablet were administered orally to dogs .

The concentration of the

drug in the plasma was detennined by high pressure liquid chromatog raphy.
In less than an hour the complex gave the maximum plasma level of 166.9 _:
22.4ng/ml, which was 8. 6 times as high as that of cinnarizine alone.
This initial increase in drug absorption might be due (according to the
authors) to the 30 times higher dissolution rate of the complex than that
of intact cinnarizine alone;

however, there was no significant
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difference between the areas under the plasma concentration-time curves
(AUC).

The AUC of cinnarizine and its complex up to eight hours was

267.2 .:!: 102.9 and 374.2 .:!: 97.2ng · h/ ml, respectively.

This might be due

(authors' opinio n) to the large stability constant of the complex,
estimated to be approximately 6.2 x 10 3M- l in water at 20°c.
Fremming and Weyermann (102), investigated the absorption of an
orally administered salicylic acid and its beta - cyclodextrin complex in
ten human volunteers (7 male and 3 female).

The percentage of absorbed

salicylic acid at a given time was reported as follows.

From salicylic

acid in one hour 24.8%, whereas from the complex 43.0% appeared in the
blood; in two hours the values were 56 .8% and 82.5%, respectively.
Hence, a significant difference in blood level was reported .
Nambu, N. ,

~·

(103), have reported the bioavailability of the

powdered inclusion compounds with beta-cyclodextrin of four kinds of
nonsteroidal anti - inflamatory drugs and the freeze dried drug alone.
These drugs were flufenamic acid (FFA), ibuprofen (! PE ) , ketoprofen (KPF )
and indomethacin (IMC).

This study was done on three healthy albino

rabbits and six healthy male beagle dogs.

The drugs were administered to

the stomach of each rabbit through a sonde, using fresh suspensions
containing lOOmg of FFA, 200mg of !PF, lOOmg of KPF, and 50mg of IMC.

In

the case of the beagle dogs, the cross-over method was used with an
interval of one week.

The dogs were administered lOOmg of KPF orally as

a powder.

The bioavailability results of only this drug in dogs were

reported.

The plasma concentration of FFA was determined by fluorescence

spectrophotometer, the concentracitons of !PF, KPF, and IMC were
determined by gas chromatography.

The details of the analytical methods

and conditions such as sensitivity, reproducibility, accuracy, were not
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reported.

The FFA inclusion compound gave a high blood level compared

with the simply freeze dried drug.
reported.

The actual blood level was not

It was observed or estimated from the blood level curve that

the maximum plasma concentrations of FFA freeze dried inclusion compound
and freeze dried FFA were approximately 6ug/ml . and 2.5ug/ml,
respectively.

The time to reach maximum plasma concentration was

approximately one hour.

However, there was a double maxima, and it is in

the authors' opinion that further investigation is required to elucidate
the double maxima on the blood level curve.
observed in the case of IMC.

A similar effect was

In the case of !PF the freeze dried complex

gave a high blood level compared to the simply freeze dried drug.
exact plasma concentration was not reported.

The

Among the four drugs, KPF

gave the highest blood level, and no double maxima phenomenon was
observed.

The KPF recovery in the urine was 60.5% for the freeze dried

inclusion compound and 40.0% for the simply freeze-dried drug.

In order

to confirm the results obtained in the rabbits, a bioavailability study
was carried out using beagle dogs. In the area under the curve up to four
hours after administration the ratio was found to be 1.52 to 1.00 for the
inclusion compound KPF against the simply freeze dried drug.

There was a

significant difference in the blood levels up to four hours, as
determined by Student's-t-test.
Cyclodextrin complexes are not necessarily limited to oral use.
Cyclodextrin complexes in suppositories have improved dissolution and
bioavailability.

For instance, Iwaoku, R.

~-

(104), studied the

absorption of phenobarbital from suppositories containing
beta-cyclodextrin.

In this study, five male albino rabbits were used,

and a test suppository containing approximatel y 50mg phenobarbital was
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inserted into the rectum.

An interval of more than two days was all owed

prior to the next experiment.

Assay of phenobarbital in blood samples

withdrawn from the ear vein was performed by gas chromatography; however,
details of assay sensitivity, reproducibility were not reported.

Blood

levels of the drug containing the complex were muth higher during the
initial three hour period.

There was a statistically significant

difference in the extent of absorption compared to the rate of
absorption.
The literature is replete with other reports on application of
cyclodextrin complexes for the bioavailability of various drugs

(105-117).
Summarizing the biological availability data, the author of this
thesis feels as follows: Some of the published data demonstrate
unambiguously that the cyclodextrin inclusion compounds are shown to
improve bioavailability (in animals as well as in humans) of certain
drugs .

However, some of the reported studies are not well designed or

may lack certain essential details; hence, reported results should be
accepted with some reservations.

However, there is a substantial number

of papers that show that orally administered cyclodextrins are safe and
useful in the enhancement of bioavailability.

There are some cases in

which it has been shown that cyclodextrins are not only useful in the
enhancement of bioavailability but also in the reduction of side effects .
It has been reported that for digoxin there was a correlation between..!..!!
vitro dissolution enhancement by complexation and in vivo absorption in
animals.
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7. Target organ oriented dosage forms

It is understood by the author of this thesis that certain research
groups in the U. S. pharmaceutical industry are exploring the possibility
of developing drug delivery systems containing cyclodextrins for target
organ oriented dosage forms.

In particular, they are focussing their

attention on systems containing drugs administered by the parenteral
route for the treatment of cancer.
G-The development process for a new pharmaceutical dosage form
Today the discovery, development, and marketing of a new drug is a
time consuming and costly procedure. The development of a new drug
usually begins with a decision made by the scientific advisory board of a
pharmaceutical company.

When the decision is made to create a drug for

use in a particular state,

virtually all departments within the company

or institute become involved in its development, such as chemical and
biological research, pharmaceutical development, regulatory department,
etc. This multifaceted approach is frequently so complex that for this
reason at first only regulatory and technical aspects are dicussed.
1. Regulatory aspects
When the Federal Food, Drug, and Cosmetic Act of 1938 was passed, a
new era of drug development began. Prior to the institution of clinical
testing in humans, a Notice of Claimed Investigational Exemption for a
new drug must be filed with the Food and Drug Administration (FDA ) by the
sponsor . This form is also referred to as an IND or investigational new
drug. These regulations appear in section 505 of the act (118-120). A "
new drug " is one not presently recognized by experts in the field of
clinical pharmacology to be safe and effective based on currently
available clinical evidence. All the definitions of a new drug may be
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found in the FDA consumer (121). The Supreme Court held in FDA: Prem that
" new drug " could include a new· dosage form, not just a new chemical
entity. Originally a sponsor could begin clinical trials immediatel y
after filing his IN D; today, however, the regulations provide for a
30-day waiting period after which, if the FDA has not responded
negatively, the clinical trials may commence. The sponsor, upon
completion of a sufficient amount of clinical work to demonstrate the
safety and effectiveness of the new drug for the use or uses for which it
is intended, may then submit a new drug application (NOA) to the FDA.
This application must include: (a) detailed reports of the preclinical
studies, (b) reports of all clinical studies, (c) information on the
composition and manufacture of the drug and on the controls and
facilities used in its manufacture according to current good
manufacturing practices (CGMPs ) , good clinical practices (GCPs ) , etc .,
(d) samples of the drug and its labeling.

Once a new drug application

(NOA) is approved, any change in the manufacturing, packaging, or other
physical properties of the drug that may have an effect on safety and
effectiveness must be covered by a supplemental new drug application.
Because of today's myriad regulations, the NOA submission has become a
compilation of information that could be compared in size to any one of
the well known encyclopedias. Currently, the period f rom the time of
synthesis of a compound to its release for marketing is genera l ly some
ten-year or longer (122-124 ) . The FDA does try to minimize duplication of
effort in preparing application for drugs about which some of the needed
information is already available, by allowing use of that informati on
with assurance that the new product will be equivalent to established
marketed products. In this regard, the detailed description of the
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concept of an abbreviated new drug application (ANDA) was published in
1975 (125). Unlike the NOA, which requires submission of well controlled
clinical studies to demonstrate effectiveness, data to show saftey, and
detailed description of the manufacturing and packaging of a drug as well
as stability data, the ANDA requires the following: a description of the
components and composition of the dosage form to be marketed; brief
statements that identify the place where the drug is to be manufactured;
the name of the supplier of the active ingredients; an outline of the
methods and facilities used in the manufacture and package, etc. (126).
The purpose of the ANDA procedure is to eliminate uncessary and costly
animal and human experimentaion and to make all drug substances not
covered by patents readily available to the consumer in a competitve
market.

As discussed in the sections B and C of this introduction,

detailed studies of the metabolism and toxicity have shown that the
orally administered beta-cyclodextrin is innocuous. The cyclodextrins
administered in high doses subcutaneously, intraperitoneally, or
intravenously can induce renal damages in the rat, but at lower doses the
compound can be administered without any ill effects (20,21). Discussion
with people from the pharmaceutical industry suggests that several
companies are working on the formulation and evaluation of pharmaceutical
products containing cyclodextrins, while other companies are waiting to
see a cost reduction and improved availability of cyclodextrins before
proceeding with their studies . For instance, Squibb is evaluating
parenteral administration of a pharmaceutical product containing
cyclodextrin, while in Japan prostaglandin El is now commercially
available ;n the form of its cyclodextrin complex (15,23).
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2. Technical aspects
The development of a pharmaceutical formulation involves a number of
considerations, such as, physico-chemical stability, availability of
materials, cost factors, equipment, proper facilities, etc. As previously
mentioned in section F of this introduction, cyclodextrins can be used
for the preparation of in clusion compounds which demonstrate improved
physico-chemical stability, dissolution, bioavailability, etc., of
pharmaceuticals. At present, even though the cyclodextrins are somewhat
expensive for large scale use because of their monumental potential in
various fields, in the future the cost of the cyclodextrins may well
become more reasonable for pharmaceutical purposes.

When a formulator is

called on to develop a suitable dosage form for a new drug, he or she
would first consider solid dosage forms.

Formulation and stability

problems arise less frequently with solid dosage forms than with liquid
pharmaceutical preparations (127). However, the formulations of solid
dosage forms are not an easy task. The development of a solid dosage form
can be traced through three stages; formulation design, process
development, and process validation, prior to actual production. The
process development and validation are often considered as a separate
stage in dosage form development. The technical aspects of solid dosage
forms are as follows.
a. The determination of chemical and physical characteristics of the
active ingredient and its compatibility with potential formulation
ingredients.
b. The determination of formulation tolerances, flow characteristics,
compressibility, selectivity of methods of manufacturing, etc.
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c. The evaluation of the final product to meet requirements for a variety
of properties such as, appearance, hardness, friability, weight
variation, disintegration, dissolution, consumer acceptability, etc.
Some or all of these evaluations ought to be done in order to
develop a solid dosage fonn. Whe n a fonnulator faces . the problem of
getting sufficient quantity of active ingredients, as is quite common, an
innovative modification of techniques to a semi-micro scale may well be
needed.

In this thesis some of these problems are considered and

possible solutions are developed.
H-· Objectives of this study
As has been noted in previous section of this introduction, the
literature has a wealth of publications which report on the ability of
cyclodextrins ( especially beta -cyclodextrin ) to fonn inclusion
compounds with a wide variety of drugs and other guest molecules .
Cyclodextrin complexes have attracted a number of different types of
scientific study ( for example, some biochemists have used cyclodextrin
complexes as a model for evaluating enzyme activity) . A number of
possible phannaceutical applications of cyclodextrins have been
suggested . In particular, there are abundant data which clearly
demonstrate that, for some drugs, chemical or physical stability,
organoleptic properties, and dissolution can be radically

im~roved

by use

of cyclodextrins.
The literature is replete with papers which report laboratory
studies of the interaction of a wide variety of drugs with cyclodextrins.
The number of interaction studies described in the literature is almost
equal to the number of researchers in the phannaceutical field. However,
there is a distinct paucity of papers which describe how such .inclusion
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compounds can be conveniently incorporated into pharmaceutical dosage
forms. From the pharmaceutical point of view , if an inclusion compound
with cyclodextrins is provided i n the solid powdered form, it may be more
widely used, since it is especially convenient for oral administration.
However, there have been very few reports published concerning

t~e

inclusion compounds obtained in the solid powdered form. Additionally ,
although a number of methods are described in the literature for the
production of the drug-cyclodextrin inclusion compounds at the laboratory
level, little attention appears to have been given to producing these
products at the pilot scale or manufacturing level. The success of a new
drug or drug-complex depends on the development of practical formulations
which can be readily processed by an economically viable method for
general use.
The objectives of the present study are:
1. To prepare some drug-betacyclodextrin inclusion compounds in the solid
powdered form by various techniques, with a view to providing information
concerning which methods are most likely to be of use commercially.
2. To investigate properties of the complexes in aqueous solution and in
solid state.
3. To evaluate the preformulation properties of inclusion compounds , such
as, bulk properties, flow cha racteristics, compressibility ,

dissolution,

etc.
4. To accomplish preliminary la boratory scale-up studies .
5. To prepare and evaluate potentially commercially acceptable
pharmaceutical dosage forms of selected drugs.
The drugs selected for this study are ampicillin, phenobarbitone,
and phenytoin. These compounds have a wide range of pharmacologic, and
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physico-chemical properties and therefore allow us to explore a variety
of different formulation and processing problems .
Data published by other authors ( post Jan.1982 ) are discussed,
together with the data obtained in this study in the Result and
Discussion section of this thesis. It is noteworthy that despite the wide
interest in the pharmaceutical exploitation of cyclodextrins there is at
the time of writing ( June 1985 ) still no pharmaceutical product
containing cyclodextrins approved for marketing in the U. S.
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I I EXPERIMENTAL

A-Materials
1. Drugs
Ampicillin anhydrous (43F -0746)
(S igma Chemical Company, St. Louis, MO)
Phenobarbitone (Gl9204F04)
(Amend Drug and Chemical Co . , Irvington, NJ}
Phenytoin (63F-3449}
(Sigma Chemical Company, Co., Irvington, NJ)
2. Fonnulation components and chemicals
Acetonitrile (724629)
(Fish er Scientific Company, Fair Lawn, NJ)
Ammonium hydroxide (E701005 )
(Allied Chemical Division, Morrison, NJ)
Boric acid (710413)
(Ame nd Drug and Chemical Co., Irvington, NJ)
Citric acid (z6698M31 )
(Amend Drug and Chemical Co., Irvington, NJ)
Colloidal magnesium alluminum silicate (82470)
(R .T. Vanderbilt Compa ny Inc . , New York, NY)
Dicalcium phosphate dihydrate (9187)
(Encompress , Edward Mendell Co ., Cannel, NY)
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Dimethylacetamide (33 F-0831 )
(S igma Chemical Company, St. Louis, MO
Ethanol
(U.S. Industria l Chemicals, Inc., Newark, NJ)
Glycerol (J26123K29)
(Ruger Chemical Co., Irv ington, NJ )
Hydrochloric acid (026490 )
(E.I. Dupont De Nemours & Co., Inc ., Wilmington, DE )
Magnesium carbonate (27061M31)
(Ruger Chemical Co., Irvington, NJ )
Magnesium stearate (772716)
(Fisher Scientific Company, Fair Lawn, NJ)
Methanol (7 43275 )
(Fisher Scientific Company, Fair Lawn, NJ)
Methyl cellulose 1500cps (MM121926c )
(Ruger Chemical Co., Irvington, NJ
Microcrystalline cellulose (1 4261 )
(Avicel PH 101, FMC corporation, Philadelphia, PA )
Monobasic potassium phosphate (722964 )
(Fisher Scientific Company, Fair Lawn, NJ)
Peppennint oil (J26477Ml6 )
(Amend Drug and Chemical Co., Irvington, NJ )
Phosphoric acid (y-115 )
(All ied Chemical Division, Morrison, NJ)
Polyethylene glycol 200 (B3459A26 )
(Ruger Chemical Co ., Irvingt on, NJ)
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Polyethylene glycol 300 (Jl9526Bl0)
(Ruger Chemical Co., Irvington, NJ)
Polyethylene glycol 400 (Dl4508k06)
(Ruger Chemical Co., Irvington, NJ)
Potassium chloride (950373)
(J.T. Baker Chemical Co., Phillipsburg, NJ)
Propylene glycol (025395)
(J.T. Baker Chemical Co . , Phillipsburg, NJ)
Sodium hydroxide (720859)
(Fisher Scientific Company, Fair Lawn, NJ)
Sodium Starch glycolate (2166 )
(Explota b, Edward Mendell Co., Carmel, NY)
Sorbitol (H22101 P20 )
(Ruger Chemical Co., Irvington, NJ)
Spearment oil (H l8261!10 )
(Amend Drug and Chemical Co., Irvington, NJ)
Sugar
(Sweet Life Products Corp. , Suffi e1d, CT)

3.

Equipment

Apple Computer and Printer
(Apple Computer, Cupertino, CA)
Brinkmann Mini Spray Drier
(B rinkmann Instruments, Inc., Westbury, NY)
Carver Laboratory Press
(Fred S. Carver Inc., Menobonel Falls, WI)
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Chart Strip Recorder
(Cole- Parmer Instrument Company, Chicago, IL)
Constant Temperature Refrigerated Bath
(Blue M Electric Company, Blue Island, IL)
Differential Calorimeter
(Perkin Elmer, Norwalk, CT)
Erweka Hardness Tester
(Erweka Apparatabau, W. Germany)
Fi sher-Wheel Sieve Shaker
(Central Scientific Company, Chicago, IL)
Fixed Wavelength Detector
(Water Associates, Milford, MA)
Hull Freeze Drier
(Hull Corp. Hatboro, PA)
Infrared Sjpectrophotometer
(Perkin Elmer, 457, Grating Infrared Spectophotomer, NJ)
Kitchen Aid Mixer
(The Hobart Mfg . Co., Troy, OH)
Markson Digital pH meter
(Markson, Science Inc . , Delmar, CA)
Mettler Balances
(Mettler Instrument Corporation, Princeton, NJ)
Mettler Digital /Analog converter
(Mettler Instrument Corporation, Princeton, NJ)
Microscope
(Leitz, Wetzlar, Germany)
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Millipore Filter Holder
(Millipore Corporation, Bedford , MA)
Millipore Vacuum Pump
(Millipore Corporation, Bedford, MA)
uBondapak

c18

(Water Associates, Milford, MA)
Ohaus Moisture Balance
(Ohaus Scale Corporation, Florham Park, NJ)
Proton Magnetic Resonance
(Varian EM390, Palo Alto, CA)
Roche Friabilator
(Erweka Abrasion Tester, Erweka GmbH, Frankfurt, Germany)
Solvent Delivery System
(Water Associates, Milford, MA)
Stokes Hot Air Oven
(S tokes-Penwalt Co., East Stroudsberg, PA)
Stokes Model F Tablet Press
(Stokes - Penwalt Co., East Stroudsberg, PA)
Stokes Model B2 Rotary Tablet Press
(Stokes-Penwa lt Co., East Stroudsberg, PA )
Thickness Gauge
(Va nderkamp, Vankel Ind ustries, Chatham, CA)
Turbula Rapid Blender
(Wiky A. Bachoven Co., Troy, OH)
USP Disintergration Apparatus
(Vanderkamp, Vankel Industries , Chatham, CA)

l
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USP Dissolution Apparatus
(Vanderkamp, Vankel Industrues, Chatham, CA)
UV Spectrophotometer
(Hitachi 200, Perking Elmer Corporation, Norwalk, CT)
Virtis Freeze Drier
(Virtis Company, Gardiner, NY)
WISP 7108
(Wate r Associates, Milford, MA)
X-ray Diffractometer
(Philips Electronin Division, Mount Vernon, NY)
Glassware and common laboratory equipment as available in
the College of Pharmacy
B- Methods
1. Studies of the interaction of beta -cyclodextrin with
ampicillin, phenobarbitone and phenytoin.
a.

Ampicillin

Inte raction of beta-cyclodextrin with ampicillin was assessed by studying
the influence of the beta-cyclodextrin on the rate of hydrolysis of the
ampicillin at 37oC in hydrochloric acid buffer of pH 2. 0. The
hydrochloric acid buffer was prepared in accordance with USP XX (128 ) . A
known amount of ampicillin was added to each of a series of different
molar concentrations of the beta-cyclodextrin solution. · The molar
concentrations of ampicillin to beta-cyclodextrin were 1:1.0, 1:1.5, and
1:2 . 0. The solutions were transfered into a 100 ml volumetric flask,
stoppered and then kept at 37oC in constant temperature bath. Samples
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were taken at 0,3,6,9, and 12-hour time intervals. After appropriate
dilution all samples were assayed by High Pressure Liquid Chromatogarphy
(HPLC).
V.,

This assay procedure was

~.(129).

basically that described by Das Gupta,

This method has been validated and is currently in

routine use in a pharmaceutical company.
fully validate the method again.

Hence there was no need to

However, the reproducibility, accuracy

and precision were determined, these values are reported in Appendix A,
1.

The HPLC system consisted of a solvent delivery system, the WISP
(Waters Intelligence Sample Processor), and a variable wavelength
detector.

c18

The separation was performed on a 3.9mm (id) x 30cm uBondapack

(reversed phase) column. The chromatographic peaks were recorded

using a chart recorder.

The mobile phase employed in the analysis of

ampicillin consisted of 1.4gm. / l potassium phosphate in
acetonitrile/water (7:93 v/v).

The pH was adjusted to 4.1 with

phosphoric acid. The following chromatographic conditions were employed
(129): flow rate= 2.0ml/min.; detector wavelength - 240nm; 0. 05 AFUs
(Absorptions Full Scale Units); and injection volume 20 ul.
A series of dilutions from a standard solution {3 . 15 x 10- 3 M) was
made and the peak height was determined. A calibrution curve was
constructed by plotting the peak height of each standard dilution against
its known concentration {Appendix A, 1).
Beer's law states:
A

Where A

abc

absorbance or peak height
a = absorptivity

Eq .

(4)
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b
c

sample path length

= concentration

Applying Beer's law, the slope of the straight line obtained by the
absorbance (peak height in this case) as a function of concentration is
equivalent to the term ab in Eq. (4).
By rearranging Eq. (4) to
c

= A/slope

Eq .

(5)

The concentration of an unknown sample may be calculated.
A graph of log concentration of the drug as a function of time was then
plotted. The hydrolytic degradation constant (kd) and half-life (tl /2)
with and without beta - cyclodextrin were calculated using Eqs. (6) and
(7), respectively.

kd

= - Slope

x 2.303

tl/2 = 0.693/kd

Eq .

(6)

Eq .

( 7)

The stability constant was calculated using Eq. (8) according to
Griffiths and Bender (130).
Eq.

(8)

Where ko and kc are the pseudo - first order rate constants for the
degradation of uncomplexed and complexed ampicillin, respectively. kobs
is the observed pseudo-first order rate constant, and K is the apparent
stability constant for the complex. A plot of ( kobs - ko ) as a function
of (kobs - ko) /beta - cyclodextrin concentration was then plotted. From
the slope and intercept of the plot ko, kc, and K were calculated .
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b.

Phenobarbitone

Interaction of beta-cyclodextrin with phenobarbitone was studied by
solubility analysis.

The procedure used in this study was the solubility

method of Higuchi and Lach (131).

Quantities in excess of the normal

solubility of phenobarbitone were weighed into 20-ml vials and added to
10-ml of aqueous solution containing various concentrations of
beta-cyclodextrin.

The vials were capped, sealed with a tape, and then

agitated on a mechanical shaker in a constant temperature bath at 2s 0 c
until the system reached equilibrium.

Two replicates were studied to

determine the equilibrium point by assaying the samples at 17, 24, and 40
hours as follows.

At the end of each time period, contents of the vials

were filtered through (0.45u) filter paper. Aliquot portions of the
filtrate were properly diluted and assayed for drug content .

It was

ascertained that a 24- hour time point was sufficient to reach the
equilibrium point.
Based on the principles described above in section B, l; a
calibration curve was generated (Appendix A, 2). A series of dilutions
from a standard solution (1.72 X 10- 3 M) was made and injected using the
following chromatographic conditions which are a minor modification of
the published method (132): flow rate = l.Sml / min.; detector wavelength254nm; injection volume - lOul. The same HPLC system was used as
described in section B, 1.

The mobile phase employed in the analysis of

phenobarbitone consisted of acetonitrile, methanol, and water (20 :20:60
v/v). A phase solubility diagram was constructed according to the method
described by Higuchi and Connors (47).

The stability constant was

calculated from the phase solubility diagram as described in the section
E, 1 (Eq. 1) of the introduction.
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c.

Phenytoin

Interaction of beta-cyclodextrin with phenytoin was studied by solubility
analysis. The solu bility was determined in a pH 7.0 using the Therell and
Stenhagen buffer system (133 ) .

The method was as described in section l,

b, except that the drug was assayed by ultra-violet absorption at the
wavelength of 225nm. The USP (128) value for this drug is at the
wavelength of 258nm in water.

However, at this wavelength there was no

maximum absorption observed even with the USP standard of this drug.
Hence, E cm 1% was determined as in the Isola tion and Identif icati on of
1
Grugs edited by Clarke (13 4). The value was found to be 27 . 8 which is
within 5% of the value reported by Clarke.

Hence the reported wavelength

(225nm) at which a maximum absorption was observed and taken as A~n a
given medium .

Based on the principles described in the method section

8, 1, a calibration curve was generated (A ppendi x A, 3) from a series of
dilutions of a standard solution (7 .93 x 10 -SM ).

It was determined that

the cyclodextrin did not interfere with the spectrophotometric
measurements at the concentration employed (Appe ndi x A, 4).

The

stability constant was calculated from the phase solubility diagram as
described in the section E, 1 (Eq. 1) of the introduction to this thesis.
2. Preparation of Drug-cyclodextrin complexes
a.

Solvent evaporation : Equimolar quantities of drugs and

beta -cyclodextrin were added to a 50:50 mixture of water and ethanol.
All the solids were dissolved by warming (up to 40-45oC) and stirring the
mixture .

The solution was kept at room temperature for approximately

five days to allow
was checked

complete evaporation of solvents.

using a moisture balance.

Moisture content
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b.

Kneading : Equimolar quantities of drugs and beta-cyclodextrin were

dry mixed thoroughly in a Kitchen- Aid Mixer for about 30-min. This
mixture was kneaded with a small amount of water to make a slurry and the
slurry was stirred well .

The slurry was allowed to stand for about an

hour and then dried at 35°c

for _approximately two-hours and screened

through 20 mesh screen.
c.

Freeze drying : Equimolar quantities of drugs and beta-cyclodextrin

were dissolved in water. It was necessary to add in some cases less than
2 % of 28 % ammonium hydroxide solution to dissolve the drug completely.
The solution was filtered through .a 100 mesh screen and then freeze dried
using a laboratory model and as well as an industrial model freeze drier.
The details of the freeze drying operating conditions are given in Table
II.

This freeze drying procedure was basically that described by

Ku rozumi,
d.

~ {5 1 ) .

Spray drying : As described in the freeze drying procedure, solutions

were prepared and spray dried using a laboratory model spray drier.

The

details of the operating conditions are in Table III.
3.
a.

Evaluation of the complexes

Stability and solubility analysis

As described in the section 8,

of the introduction, stability and solubility studies were carried out.
b.

Infrared ( IR) spectroscopy

Approximately one to two mg of drug was

ground throughly with 80-90mg of potassium bromide (KBr) in order to give
a thin transparent disk. Then IR spectra were measured using Perkin
Elmer, 457, grating infrared spectrophotometer.

Dr. Sandeep Gupta

(Department of Pharmacognosy, University of Rhode Island ) supervised this
work.
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Table II
-Freeze drying procedure-

*1.

Prefreeze the solution to be freeze dried.

2.

Turn on refrigeration before turning on vacuum pump.

3.

Do not proceed unless the temperature is between -40 tO - 50oC or
lower.

*4 .

When the temperature is -40oC or lower, load samples.

5.

Turn vacuum pump on

6.

Operate vacuum pump ballast closed.

7.

When the desired vacuum or pressure is reached (approximately
200u), turn the heater on.

(

~*8.

Ory the product between 40 to 50, till a marked decrease in
chamber pressure or vacuum occurs.

9.

When the drying cycle is complete, turn off heater and vacu um .

10.

Slowly break the vacuum.

11.

Turn off refrigeration.

12.

Unload the product.

---------- ------------ -------~-- - ~-------------------------------------

*- Necessary only for laboratory freeze drier.
~·- Difficult to monitor the product ·temperature and chamber pressure

using a laboratory freeze drier.
~·-

These two parameters were monitored using an i ndustrial model freeze

drier (Appendix B).
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Table III
Spray drying procedure

~·

Heat the unit to the desired temperature.

e.

As soon as the inlet temperature has stabilized, adjust and stabilize

~he outlet temperature.

p.

Turn on compressed air pressure to the desired value.

~·

When the desired values have been achieved, the unit is ready for the

spraying operation.
5. Adjust the aspirator to regulate the spraying.

~-

Following conditions were used for the present study.
Inlet temperature- 120 to 140oC
Outlet temperature - 80 to 90oC
Air pressure - 70 to 80 PSI
Pump scale Aspirator scale - 10
Heating scale - 10
Flow indicator scale - 50
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c.

X-ray diffractometry: Specimens were placed in a shallow

squareshaped glass holder. The holder was flat on one side, approximately
measuring

1-5/16" x 1-3/16" x 1/8 ".

The (28) 10- 50° diffraction angles

were measured from the CrKalpha (2.29 A0 ) at a scanning speed of 2°/min.
and 500 cycles per second .

Dr. Thomas Rockett (Department of Chemical

Engineering, University of Rhode Island) supervised and advised in the
interpretation of spectra.
d.

Measurement of lattice parameters : A single crystal of the complex

was obtained from the solvent evaporation method, and lattice parameters
were measured using Weissenburg and Precession Photographs .

Dr. Clair

Cheer (Department of Chemistry, University of Rhode Island) supervised
and assisted in this work.
e.

Proton magnetic resonance (PMR) spectroscopy : Approximately 10- 20mg

of samples were dissolved in deuterium oxide solvent and filtered (a
cotton plug was used as a filter on the pipet tip ) .

The PMR spectra were

taken using a Varian EM 390, spectrometer. Due to deuterium oxide fixed
position, this peak was used as an internal standard in the comparision
of the chemical shifts of the host and the guest.

Dr . Nandu Bongale and

Mr. Amarendra Mikkeleni (Deparment of Medicinal Chemistry, University of
Rhode Island) supervised and advised in the interpretation of spectra.
f.

Differential scanning calorimetry (DSC) : Samples of approximately

5- lOmg were placed in aluminum pans and the 120-400°c
was measured using a Perkin Elmer Calorimeter.
0

s

temperature range

The heating rate was

/ min . and the range was Smeal/sec. at a chart speed of 2cm/min.

Dr.

Mahendra Dedhiya (Miles Pharmaceuticals, West Heaven, CT.) supervised
this work.
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g.

Photomicrographs : Samples were placed on a mounting slide with a

drop or two drops of low refraction liquid. Microphotographs were taken
on a Leitz microscope.

All samples were photographed using the same

liquid at 125x magnification .
4.
a.

Properties of drug-cyclodextrin complexes

Drug content in the freeze dried complex
(i) Phenobarbitone beta-cyclodextrin complex

Approximately lDOmg of a weighed sample of

the complex was dissolved in

lOOml water and lml was diluted to lOml. Three injections were made in
triplicate, and concentration was determined by HPLC as described in the
experimental section B, lb.
(ii) Phenytoin beta-cyclodextrin complex
Approximately lOOmg of a weighed sample of the

complex was

dissolved in lOOml of a pH 9. 0 buffer {Therell and Stenhagen buffer
system) . Samples were appropriately diluted for spectrophotometric
analysis at 225nm .

The concentration of the drug was determined as

described in the experimental section B, le .
b. Scale-up and Yield improvement
The freeze drying method for the preparation of the complexes was
scaled-up from a laboratory freeze drier to an industrial model freeze
drier.

The yield was improved from 57% to more than 95%.

This

significant improvement in the yield was achieved from an open tray
drying system to a closed tray drying system. These systems are depicted
in Figures given the Results and Discussion of this thesis.
c.

Particle size distribution
A nest of sieves, sizes (U. S. Standard) 20,40,60,80,100,140, and

200, was used to measure the particle size distribution.

A known amount
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of sample was placed on the top screen and the sieve stack was shaken for
30-min. on a Fisher-Wheel Sieve Shaker.

The fractions in each sieve were

collected, weighed and percent underweight values were calculated.
d.

Bulk and Tap densities
A sample of 50 cm 3 of powder was carefully introduced into .a tared
100 cm 3 graduated cylinder, weighed, tapped 100 times and measured the
resulted volume. If V is the tapped volume in cm 3 of W grams of material
in the cylinder, then the tapped density in gm/cm 3 is given by
Td

W/V

Eq.

(9)

Eq.

( 10)

and bulk density
Bd = W/50

Where Td and Bd represent the tapped and bulk densities,
respective 1y.
Compressibility was then determined as follows.
% Compressibility= ( Td - Bd )/Td X 100

e.

Eq. ( 11)

Moisture content
The moisture content of each material was determined using an Ohaus

Moisture Balance, operating at a temperature of so 0 c (4 watt light) for a
period of 30-min.

The percent loss was directly read from the balance.

f. Flowability studies
Powder flow was determined using a rec ording flow meter (Fig . 6) .
The powder flow meter design, procedure, calculations of linearity index,
etc., were developed and described by Jordan and Rhodes (135), and
Rudnic,~.(136).

The same procedure was used in this study.

However, the use of the flow meter was extended to study the effects of
small mass and geometry on flow rates.

This miniturization of flow

studies was undertaken so that flow data could be obtained under
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conditions when only small amounts of material are

available.

This

makes recording powder flowmeter data useful in numerous quality control
and in - process powder flow testing situations.

Hence, a stainless steel

hopper, a conical glass funnel, measuring 12cm (to p diameter ) by 38cm
(length) and l . 9cm (orifice diameter), and a cylidrical glass funnel,
measuring Scm (top diameter ) by 26.Scm (l ength ) and l.5cm (o rifice
diameter) were used to determine mass and geometry effects on flow rates .
The delivery of a specified weight was timed, then mass flow rates were
determined for three runs of each system.
rate, and the flow rate

The value is only a mean flow

change during the flow process.

A measure of

this change is the linearity value, which was caculated as follows.
fl : (r

2

- 0.8) X 100

Eq.

( 12 )

Where fl is the powder flow index and r 2 is the least squares
correlation coefficient .
g.

Compressibility studies
Compression measurments were made using an instrumented Stokes B

rotary press, located in the Department of Pharmaceutics of the
University of Rhode Island.

This tablet press was instrumented with four

piezo-electric transducers and interfaced with an Apple Il e computer.
The software to the Apple computer (developed by Mr. J. Hoblitzell)
enabled the calculation of compression and ejection forces.

In additi on,

it also calculates mean area under the compression, ejection curves, mean
area to height ratio for compression and standard deviation for all the
above parameters.
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C- Formulation of liquid dosage forms.
Solution preparation and evaluation

1.

The compositions of two potential f ormulations are shown in Tab les
IV and V. Once the dosage form was prepared, its properties were
evaluated on daily basis to weekly, and then one month.

These

evaluations were as follows:
a.

Visual examination for clarity, such as, precipitation, crystal

growth, change in color, odor, etc.
b.

Assay of drug content (HPLC) after

samples had been stored at room

temperature for one month.
2.

Suspension preparation and evaluation

A final suspension formula is given in Table VI. The suspension was
evaluated as follows .
a.

Visual examination

The supernatants of the stored suspensions were

examined for evidence of opalescene caused by very small particles, which
are slow to settle .
b.

Sedimentation study : The sedimentation volumes were recorded in

terms of the ultimate settled height (Hu), to the original height Ho
(137).
% Sediment

c.

= Hu / Ho

Eq.

( 13)

Measurement of redispersibility study : To standardize the evaluation

of redispersibility a blender was modified ( Fig . 7), such that the
cylinder would turn through 360° at a speed of 20-22 rpm.

The number of

revolutions necessary to restore the suspension to homogen ity was
recorded. Similar methods of evaluation have been reported in the
literature ( 137).
d. Photomicrographs

As described in the experimental section B, 3g .
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Table IV
Phenobarbitone solution formulation # 1

% Ingredients
Phenobarbitone beta-cyclodextrin complex *

2.0

Glycero l

40 . 0

Sorbi tol

20.0

Simple Syrup **
Distilled water to make

20. 0
100 . 00

Dose ; 20mg/5m l

* - Contains 20% dru g

** - Prepared according to the USP XX
Preparatio n - Dissolved the complex in the mixture of glycerol , sorbito l,
and simple syru p.
volume .

Sufficient water was added to the mixture to desired

The final product was mixed well by means of a magnetic stirrer

and filtered throug h 0. 45u filter paper. Upon filtration the product was
flavored (Orange oil approximately

three drops ) and mixed well .
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Table V
Phenobarbitone solutio n fonnulation

2

% Ingredie nts

Phenobarbitpne beta-cyclodetrin comp l ex
Glycerol

10.0

Sorbito l

40.0

Simple Syurp

20.0

Distilled water to mak e

Preparatio n

2.0

As described i n Table IV.

100.0

63

Table VI
Phenytoin suspensio n fonnulation

% Ingredients

Phenytoin beta-cyclodextrin comp lex *

10.0

50 : 50 mixture of water and glycero l
quantity sufficient to mak e

Dose

100.0

= 100mg/5m l

* Complex contains 20% drug .
Preparatio n : The complex was dispersed in the 50 : 50 mixture of water
an d glycerol an d then made up to desired vo lume.

The suspension was

homoge nized using an hand homogenize r, flavored with Banana flavor , and
mixed well by means of a Moto r Gene ralor Munomatic stirrer .

c
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V..SHAPED BLENDER
Fig. 7:

A dev ice for redispersibil i ty measurement of the
suspens io n .
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0- Formulation and evaluation of solid dosage form.
Tablet formulation and preparation are given in Table VII .

Tablets

were evaluated as follows:
a.

Appea ranee
Tablets were examined using a lOX magnifying glass for chipping

cracking, picking or mottling of the surface as an in-process check.
b.

Weight
The weight of each individual tablet was determined after dedusting.

This procedure was repeated for twenty tablets.

The data from the

tablets were analyzed for sample mean and standard deviation .
c.

Thickness
The thickness of ten tablets was determined by first dedusting, and

then placing each of them in the jaws of a micrometer.

The measurements

were recorded and analyzed for mean value and standard deviation.
d.

Hardness
The hardness of ten tablets was determined by placing each tablet in

the hardness tester (Erweka), which recorded the breaking strength of the
tablet in kilograms.

This procedure was repeated and the data were

analyzed for sample mean and standard deviation.
e.

Friability
This test is a measure of the abrasion resistance which was

determined by first weighing twenty tablets after dedusting, then placing
them in a tumbling chamber for four minutes or 100 revolutions.

The

tablets were again dedusted and weighed after tumbling, and the percent
friability was determined as follows:
% Friability

=(

Iw - Fw ) I Iw X 100

Eq.

(14)

Where Iw and Fw represent the initial and final weights, respectively.
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Table VII
Phenytoin tablet fonn ulation

% Ingredients
Phenytoin beta-cyclodextrin complex *
Sodium starch glycolate

1.50

Magnesium stearate

0.75

Microcrystalline cellulose

pose

80.00

to make

100 . 00

= 50mg/tablet

~ - Contains 20% drug

Preparati on : Preweighed complex and sodium starch glycolate (0. 75%) were
~horoughly
~sing

mixed for fifteen minutes in a Kitchen Aid Mixer, and wetted

water as a gra nulating agent.

The wet mass was seived (10 #) and

~ried at 40oC to approximately a moisture level of 5% as detennined by a
~oisture

balance.

Dried mass was reseived (20 #) to produce unifonn

granules, then mixed for ten minutes with the remaining (0.75%) sodium
starch glycolate and microcrystal line cellulose (app. 18%).
~agnesium
~ith

The

stearate was mixed in a Turbula Rapid Blender for three

the tablet matrices and tablets were compressed.

approximately 0.95cm and target weight was 312.50mg.

minute~

Punch diameter

wa~
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f.

Ease of manufacturing
The noise and vibration from the tablet press were carefully

monitored subjectively to identify any problems in manufacturing tablets.
g.

Disintegration
Tablet disintegratio n was tested using the USP apparatus, as

described in the U. S. Pharmacoepia (128).

The time needed for all the

palpable fragments to pass through the screen at the bottom of the cage
was detected visually and was recorded.

Six tablets were used in each

test, and mean and standard deviations were calculated .
h.

Dissolution
When a drug was to be measured for rate and extent of dissolution, a

sample of the lot of drug to be used was placed in various concentrations
in a spectrophotometer to measure the

max for that particular drug.

Once this value was determined, the spectrophotometer was set at that
wavelength, and each sample was analyzed for absorbance. The result was
recorded on a Beer's plot (as described in the method section B, 1) and
correlation between absorbance and concentration was recorded.

The

monograph, as it appeared in the USP (128) was used as a reference for
determining the dissolution medium for the test .

In addition,

dissolution was determined in acidic (pH 2.2) and basic media (pH 7.4).
The requried acidic and basic media were prepared in accordance with the
USP (128).

A sample of three and six tablets

wer~ · used

for each system.

The samples at specified time intervals were withdrawn and diluted with
dissolution medium to read the absorbance between 0.1 and 0.7.

Because

of the rather limited aqueous solubility of the phenytoin, samples of th e
tablets were carefully cut in to two halves and based on weighed portions
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of the tablets, dissloved drug concentrations were determined.The
concentations were determined from the Beer's plot (Appendix

A, 5).
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III Results and Discussion
The results and discussion are organ iz ed i nt o the following main
sections.
A. Phys ico- chemical properties of comple xe s
a.

Stability

b.

Solubility

c.

X-ray diffractometry

d.

Measurement of lattice parameters

e.

Differential scanning calorimetry

f.

Infrared spectroscopy

g.

Proton magnetic res onance spectroscop y

h.

Photomicrographs

B. Preparation of the complexes
a.

Solvent evaporati on

b.

Kneading

c.

Spray drying

d.

Freeze drying

C. Preparation and evaluation of dosage forms
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A. Physico-chemical properties
a. Stability
Complex formation of ampicillin with beta-cyclodextrin was studied
using different molar concentrations of the beta - cyclodextrin with an
ampicillin solution.

Figure 8. depicts the results of this study.

It is

readily evident that the beta - cyclodextrin has a stabilizing effect on
the ampicillin hydrolysis rate. The disappearance of ampicillin displayed
a pseudo-first order kinetic behavior in the solutions with or without
beta-cyclodextrin

From this figure and using equations six and seven

the observed pseudo- first order rate constants and half-lives were
calculated.

The results are repo r ted in Table {VIII) .

An analysis of

variance {ANOVA) was used to evaluate any statistical significance among
the treatments.

There was a significant difference (.£.=0. 05) between the

tre atments with 1:0 . 0 and 1:1.0 molar concentrations of ampicillin to
beta-cyclodextrin.

Furthermore, due to the single replicate nature of

the data and the constant time period between observations it was deemed
more appropriate to evaluate the colinearity of the degradation curves
presented in Fig . 8.

This analysis detected a significant difference {-<.

= 0.05) between the slopes associated with the treatments using ratios of
1:0.0 and 1:1 . 0 of ampicillin to betacyclodextrin.
the optimal ratio of beta-cyclodextrin

In order to determine

to ampicillin, a graph was

constructed by plotting the observed degradation

rate constants as a

function of the beta-cyclodextrin concentration.

As seen in Fig. 9, the

observed

degradation rate constant asymptotically approaches a minimal

value as the beta-cyclodextrin concentration is increased.

This

saturation behavior is a characteristic of reactions which proceed
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72
Table VIII
Degradation constants and Half- lives of ampicillin with different molar
concentrations of beta-cyclodextrin at pH 2.0 and 37oc

Mola r rat i o
of
Amp . and Beta-CD

1.0:0 . 0

0.052

1.3. 30

1.0:1.0

0.018

38.50

1.0:1.5

0.012

57.75

1.0:2.0

O. Oll

63.00

kd : The degradation constant of ampicillin without beta-cyclodextrin
kd' : The degradation constant of ampicillin with beta-cyclodextrin
t
t

112
112

: The half-life of ampici llin without beta-cyclodextrin
• : The half- life of amp1c1llin with beta - cyclodextrin

t

/
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through a complex prior to the rate - determining step and may be
accolTITiodated by the mechanisim illustrated in the following scheme (130) .
Amp. + Beta - CD

k

Amp.

B~ta-CD

'I

I

I

; "'~

l<o :

I

I
I

~

Degraded products ----1

Where Amp., Beta-CD, and Am p. Beta-CD, represent ampicillin,
beta-cyclo-dextrin and the inclusion complex of ampicillin with the
beta-cyclodextrin, respectively.
fa~

The pseudo-first order rate constants

the deg radati on of uncomplexed and complexed ampicillin are k0 and kc

and K is the apparent stability constant for the complex.

In Fig. 10 the

rate constants of Fig. 9 are plotted according to Eq. (8).
For example:
kobs - k0

=-

(ko bs - k0 )/K(Beta - CD) + kc - k0

A plot of kobs - k0 as a function of (ko bs - k0 )/ beta-cyclodextrin
is shown in Fig. 8.

From the slope and intercept of the plot k0 , kc, and

K were obtained and they are reported in Table (IX) .

It is clear from

the data that the complex degrades nine times slower than the drug
itself, which is an indicative of a fairly stable complex.

In addition

the calculated stability constant (458.46M- 1 ) is also characteristic of
the extent of complex formation and may be suitable for practical
application, since too labile complexes result in premature release of
the drug and too stable complexes result in a retarded or incomplete
release of the drug.

It has been reported (23) that only those complexes

with stability constant between 200 - 5000 seem to be suitable for
practical applications. The author of this thesis found no literature
data available on the ampicillin beta - cyclodextrin complex with which
compare the results from this study.

to
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Table IX
Degradation constants and stability constant of the inclusion complex of
ampicillin-beta -cyclodextrin

Deg radation constant {ko) of the drug .

5. 00 x 10- 2hr- l

Deg r adation constant {kc) of the complex

0.55 x l0 - 2hr- l

Stability

con~tant

(K) of the complex

458.46M-l
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b.

Solubility

The solubility method of Higuchi and Lach (131) was used to study
the complex formation of phenobarbitone and phenytoin .
these two drugs were studied by solubility analysis.

Interactions of
A phase solubility

diagram of phenobarbitone was constructed according to the method
described by Higuchi and Connors (47) and is depicted in Fig. 11.

There

was a five-fold increase in the solubility of phenobarbitone due t o
complex formation.

According to the authors of the phase solubility

techniques, if a plot of the total molar concentration of substrate as a
functio n of the total molar concentration of ligand and the complex is of
a 1:1 type then a straight line with a positive slope will result.

Thus,

from such plots the stability constant (K) can be calculated using Eq. 1
as foll OWS:

K = Slope/S 0 (1-Slope)
Where S0 is the solubility of the substrate ( phenobarbitone ) in t he
absence of the ligand (beta - cyclodextrin) .

In other words, S0 is the

intercept as shown in Fig. 9, and using the slope from this figure, the
stability constant can be obtained.

However, if the slope is greater

than unity, as in this case (Fig. 9), it becomes impossib l e to calculate
the stability constant using the above equation.

Hence, the derivation

of the above equation was reexamined, and it was modified to calculate an
approximate apparent stability constant as follows.
Higuchi and Connors derived the above Eq. l fr om the fol lowing
equation.
(mKSm 0 Lt )/( l+ KSm 0 ) +S 0

Eq.

( 15 )
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Where St and Lt represent the total molar concentration of substrate
and ligand, respectively .

S0 is as defined before and m is the

stoichiometric coefficient .
A pl ot of St as a fu nction of Lt for the formation of a soluble
complex should therefo re yield a straight line.

The intercept is equal

to S0 and the slope is given by:
Slope

= mKS 0m/ l+

KS m
0

Eq.

(16)

If mis known or for simplicity is equal to 1, then equation 16
becomes:
K = Slope /S 0 (1 - Slope)
Howeve r, as pointed out earlier, if the slope is greater than unity,
the assumptio n of a 1:1 complex alo ne is ma nifesting untenable, and the
calculation of the stability constant according to the above equation is
impossible.

In such cases, according to the authors of the more general

expression (Eq. 15), it may be used by assigning a value tom.
In order to determine the value of m, the complex was isolated
(preparation is discussed in Section JIB, 2) and assayed.
are reported in Table (X).

The results

Based on the percent drug content in the

complex, the value of mis calculated as follows .
The molecular weight of phenobarbitone is 232gm/mole and that of the
beta-cyclodextrin is 1135gm/mole . Hence, the number of moles in 20% of
the drug is equal to 8.62 x 10 - 2 and that of beta - cyclodextrin is equal
to 7.05 x 10- 2 . The ratio of substrate to ligand gives 1.22, indicating
that the complex formula is

s1 . 2L.

Based on these calculations a value

form was obtained and substituted into the equation(16 ) .
Slope

= mKS 0 m/ l+KS 0

By rearranging Eq . 16 to

Eq.

(16)
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Table X
Drug content in the freeze dried phenobarbitone beta-cyclodextrin
complex.

Batch No

2

Batch size (in liters)

%

Drug content

10

20.00

10

19.68

K = Slope/ S0m(m - Sl ope )
When m = 1. 2 Eq . (17) results to
K =Slope I s 1 · 2 (1.2 - Slope )

Eq.
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( 17 )

Eq. (18 )
3
The calculated apparent stability constant is 4.54 x 10 M-l by using the
0

slope and intercept values from Fig . 9. This value is close to the va l ue
(3.60 x 10 3M- 1 ) obtained by Thoma and Stewart (9). Although the
stability constant value obtained by Thoma and Stewart is cl ose t o the
value obtained in the present study, there is a discrepancy.
discrepancy can be explained as follows .

This

Firstly, the reported stability

constant value by Thoma and Stewart was from the interaction study
carried out at

30°c,

whereas, the present study was carried out at

Hence there is a temperature effect on the stability constant .

2s 0 c.

Second ly ,

unless a solid complex is isolated and its stoichiometry analyzed,
calculation of the exact stability constant may lead to an approximati on.
It is the opinion of the author of this thesis that Thoma and Stewart did
not isolate the complex to detennine the stoichiometry; hence there is a
discrepancy in the stability constant values.

Further, Higuchi and

Connors (47) also pointed out in their phase solubility techniques that
the stoichiometry and the equilibrium constants may be ambiguous
quantities .

Hence (according to them), whenever there is an ambiguity or

conflicting results, a solid complex should be isolated and its
stoichiometry analyzed and compared with a graphical estimate of the
stoichiometric ratio.

Thus, the phenobarbitone beta-cycl odextrin comp l ex

may be a molecular ratio of 1. 2:1.0, rather 1:1.
The results of the interaction of phenytoin with
beta-cyclodextrin are depicted in Fig . 12.
increase in the

There was an el even-fold

solubility of phenytoin due t o the comple x f ormati on.
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Uekama (117) reported the solubilities of several drugs in water both in
the presence and in the absence of beta-cyclodextrin.

Among the reported

drugs is phenytoin . These results are reported in Table (XI) along with
the results of the present study .

Although the results are very close to

each other there is a slight discrepancy.

This discrepancy may be due to

the concentration of cyclodextrin in the solubility study.

Since Uekama

did not use a saturated solution of beta - cyclodextrin (Table XI) , there
is a slight decrease in the total solubility of phenytoin .

However, he

obtained a higher solubility in the absence of cyclodextrin; hence, it
may be said that both results are comparable.

Uekama reported neither

the range of the cyclodextrin concentration used nor the stability
constant of the complex.
A phase solubility diagram was constructed from the solubility data
of phenytoin and is shown in Fig . 12. From this phase diagram, and using
Eq. 1, the stability constant {766M- 1 ) of the complex was obtained. As
shown in Fig. 12, in this interaction study, the slope is less than unity
and hence there was no need to determine a value for m (Eq . 16) to
calculate the stability constant.

However, a solid complex was isolated

(preparation is described in Section IIB, 2) and the drug content in the
complex was analyzed by a spectrophotometric method.
drug content in the comple x are reported in Table XII .

The results of the
Based on the drug

content in the complex, the ratio of the substrate concentration to the
ligand concentration {ob tained as described earlier) gave a value of
This value is an indication of the complex with a molecular ratio

1.05 .
of 1:1.

Lach and Cohen {40) studied the interaction of nineteen compounds
with alpha and beta-cyclodextrin.

The data in their study indicate that
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Table XI
Comparis ion of phenytoin solubility data with t he r epor t ed literature
data.

~olubi lity at 25oc

in water (ug/ml), S0

Solubility in beta-cd solution
(ug/ml ) ,

Sc / So

5c

1*28

282

10 . 00

1**25

277

11.00

-----------------------------------------------------------------------~

* Reported values (1 17)
** Detennined vlues by the author of this thesis in pH 7.00 buffer.
Concentration of the bet-cyclodextrin used:
* 13 x l0- 3M
** 15 X l0- 3M
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Table XII
Drug content in the freeze dri ed phenytoin beta-cycl odextrin complex

~atch No

Batch size (in liters)

% Drug content
18.88

*
8

18 . 30

10

18 . 90

* - Prepared by using a laboratory freeze drie r.

,-
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those drugs which are least soluble in water show the greatest increase
in solubility as a function of quantity of cyclodextrin present.

In

addition, in their study, the drugs which are low in molecular weight and
more soluble show the highest slopes.

Similar results are shown in Table

XIII, phenobarbitone shows the highest slope compared to phenytoin, since
phenobarbitone is more soluble than phenytoin .

However, increase in

solubility of phenytoin relative to its initial solubility is eleven-fold
compared to only a five - fold increase in phenobarbitone solubility.

This

increase in solubility, especially for phenytoin, has a considerable
potential in the development of suitable dosage forms.

The extent of

complex formation (as evidenced by the stability constant) of
phenobarbitone is greater than that of phenytoin.

This stronger

interaction of phenobarbitone may be due to the size of the molecule.
Since the size of the phenobarbitone molecule is smaller than the
phenytoin molecule (Table XIII),

smaller molecules may fit well into the

beta-cyclodextrin cavity to form a more stable complex.

Cohen and Lach

(36) also felt that geometrical rather than chemical factors are decisive
in determining the extent of complex formation.
c. X-ray diffractometry
The X-ray diffractometer allows us to examine the atomic arrangement
of a material, giving information on crystal geometry and structure .

It

has been reported (49, 50) that an inclusion complex can be detected
quickly and directly by the X-ray methods.

As per these reported

studies, a true inclusion complex may exist if the diffraction pattern
does not correspond to those of pure components.
Figures 13 and 14 show the X-ray diffraction patterns of phenytoin
and the beta-cyclodextrin.

As shown in the Fig. 13c, the diffraction
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Table XIII

Slopes of intera ctio n isotherms, solu bility data an d stab ility constants .

Dru g

Stability

Sl ope

constant K(M - 1 )

r

Phenobarbitone

* * Phenytoi n

4. 53 X io 3
766

1. 08

5-fold

0.0675

11- fol d

**Solubility = 7.0ug/ml in water at 24oC (138) .

C'

M. wt .

solub ility

* Solubi l ity = l. Omg/m l in wate r at 25oC ( 134) .

\

Increase in

232
25 2
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a

30

Fig. 13:
Key:

20
10
2 9 (0 )
Powder X-ray diffraction patterns
a- Phenytoin, b- Beta-cyclodextrin, c-Freeze dri ed
complex, d- Phyxical mixture of a and b.
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c

30
Fig. 14:
Key:

20
2 a (o)

10

Powde r X-ra y diffractio n pa tterns
a- Freeze dried ph enytoin, b- fre eze dried betacyclodextrin, c- Physica l mixtu re of a and b,
d- Kneaded complex. e- So 1vent evaporated come 1ex .
f- Spray dried complex.
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pattern of the freeze dried material is different from that of the pure
components and their physical mixture.

The diffraction pattern of the

physical mixture was found to be a simple superimposition of those of the
compo nents.

The X-ray diffraction pattern shown in the Fig. 14b,

i ndicates that the beta-cyclodextrin, which was originally in a
crystalline fonn (Fig . 13b), is transfonned to an amorphous state after
freeze drying.

Similarly, the phenytoin was originally in a crystalline

fonn; which did not transfonn to an amorphous state after freeze drying
of phenytoin alone (Fig. 14a);

however, the complex prepared by the

freeze drying method was transfonned to an amorphous state and indicated
t he fonnation of a new solid phase .
shown in Fi g. 13c, around 28°.

This new solid phase is clearly

The complex prepared by the other

methods, such as kneading, solvent evapo rati on , etc., did not transfonn
into an amorphous state as evidenced by the diffraction patterns (Fig.
14d and 14e).

However, unlike the physical mixture, the diffraction

patterns are not a simple superimposition of the pure components.

The

diffraction patterns of the com plexes differed from those of the physical
mixture (diffused diffraction patterns), thus i nd icating the existence of
the complex as a separate molecular species .
Seo,~(88),

studied the X-ray diffraction patterns of

spironolactone beta-cyclodextrin systems.

In their studies they also

observed that, the diffraction patterns of the physical mixtures were
simply the superimposition of each component pattern, while those of
complexes were apparently different.

Similarly, Uekama,

~

(87) ,

also interpreted the powder X- ray diffraction patterns of acetohexamide
beta-cyclodextrin complex and their physical mixture.
Tokumura,

~

In addition,

{166), also reported the X-ray diffraction patterns of
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cinnarizine beta-cyclodextrin complex and their physical mixture .

In

their results also, the diffraction pattern of the physical mixture was
found to be a simple superimposition of those of the components , and that
of the complex was apparently different.
Figures 15 and 16 show the diffraction patterns of phenobarbitone
the complex.

The X-ray diffraction patterns shown in Fig. 15b indicate

that , like phenytoin, phenobarbitone also retains its crystalline form
even after freeze drying.

However, the phenobarbitone beta-cyclodextrin

complex prepared by the freeze drying method is completely transformed to
an amorphous state (Fig . 15c).

The physical mixture pattern is a simple

superimposition of the pure components (Fig . 16c).

Hence, it is clear

that the diffraction patterns of the complex differed from that of the
physical mixtures, indicating the existence of the complex as a separate
molecular species.
d. Measurement of lattice parameters
It was possible to obtain a single crystal of the phenytoin
beta-cyclodextrin complex by the solvent evaporation method.
are reported in Table (XIV) .

The results

As shown in the Table, one of the axial

lengths (A) has almost doubled, indicating a different molecular order .
This new molecular order may be due to inclusion complexation of
phenytoin with the beta-cyclodextrin.

Based on the X-ra y resluts and

solubility characteristics, it is possible by inclusion complexation that
the axial length (A) may have changed.

However, in order to reach a

definitive conclusion, this question is deferred for further study.
Since, the author of this thesis could find no data reported in the
literature on the measurement of the lattice paramete rs of inclusion
complexes.
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a

b

d

30

Fig. 15:
Key :

0

10

2 a (o)
Powder X-ray diffraction patterns
a- Freeze dried beta-c yclodextrin, b- Freeze dried
phenibarbitone, c- Freeze dried complex, d- Spray
dried complex.
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a

30

20

10

e (o)
Fig. 16:
Key:

Powder X-ra y diffraction patterns
a- Ph enoba rbi tone, b- Freeze dr ied phenoba rbi tone,
c - Freeze dried beta - cyclode xtrin,
d- Phy si cal mixture of b a na c.
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Table XIV
Lattice parameters data

Axial length

*

l

** 2

A

B

c

21.29

10.33

15.10

42. lB

11.04

15 . 05

*- Reported values of beta - cyclodextrin unit cell dimensions .
Carbho hydrate Research, 99, 103 (1962)

**- Measured values of phenytoin beta-cyclodextrin complex prepared by
the solvent evaporation method.
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e. Differential scanning calorimetry (DSC)
Cyclodextrins complex formation may be proved by DSC.

Fig ure 17

shows the DSC curves of freeze dried phenytoin and the freeze dried
complex.

In Figs . 17 and 18 the freeze dried phenytoin and

beta-cyclodextrin gave an endothermic peak aro und 29S°C {568°K) , which
corresponds to the melting points of the phenytoin and beta-cyclodextrin.
The freeze dried complex and the physical mixture

{Figs . 17 and 18) also

gave an endothermic peak around the same temperature (Fig . 18).

However,

the pattern of the freeze dr ied complex thermogram is clearly different ·
from that of the phys i cal mixtu re.

These thermograms suggest that there

is some interaction in the freeze dried complex but not in the physical
mixture.

Because of the very narrow range of the melting points of the

phenytoin and beta-cyclodextrin (Table XV), it was not possible to
elucidate clearly the presence of the inclusion complex .

In order to

demonstrate the absence of the inclusion complex in the physica l mixture,
DSC cu rves of phenobarbitone and the beta - cyclodextrin were depicted as
shown in Figs. 19 and 20 .

Since there is clearly a wide range of

difference in melting points (Table XV), it was possible to distinguish
the presence and absence of the true inclusion complex by observing the
endothermic peaks of the two different molecules .

This phenomenon is

elucidated in the Fig . 20 . These thermograms strongly suggest the
presence of the inclusion complex in the freeze dried material but not in
the physical mixture.
Similarly, Kurozumi,

~

{5 1) have found that freeze dried

mefenamic acid gives at 232oC an endothermic peak; its mechanical mixture
also gives the same peak at the same temperature; but the complex
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Table XV
Melting points data on phenytoin, phenobarbitone and beta-cyclodextrin.

Drug

Melting Point (°C)

Phenytoin

295 - 298

Phenoba rb itone

174 - 177

Beta-cyclodextrin

300 - 310
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prepared by the freeze drying method does not.

Hence, this behavior is

usually a characteristic of inclusion complexes.
f. Infrared (IR) spectroscopy
Figures

21 and 22 show the IR spectra of the phenytoin and

beta -cyclodextrin.

The complex formation may be proved by IR because

bands due to the included part of the guest molecule are generally
shifted or their intensities are altered.
Figs.

However, the results shown in

21 and 22 can not be readily interpreted in an unambiguous manner

since the physical mixture and the freeze dried complex show by and large
similar patterns.

This similarity in the patterns of freeze dried

complex and the physical mixture can be explained as follows .
(i) In general, the mass of the guest molecule in a complex does not
exceed more than 25% (8) of the mass of the complex.
(ii) This phenytoin beta-cyclodextrin complex contains around 20% drug in
the complex (Table XII).
For IR spectra , one or two mg of sample is used with 80- 90 mg of
potassium bromide.

Hence, in the one or two mg complex, the active drug

content is only a few micrograms .

Therefore, if any bands are altered

due to the included part of the guest molecules, these alterations may
possibly obscure the spectrum of the host.

Similar exp la inations are

reported in the literature (8) in the study of pyrethrin-cycl odextrin
complexes.
g. Proton magnetic resonance (PMR) spectroscopy
Recently, nuclear magnetic resonance (NMR ) methods have contributed
greatly to the understanding of the cyclodextrin interaction with
different guest molecules.

The PMR investigation of the complexes of

cyclodextrins was technically difficult due to the low solubility of the
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complexes in deuterium oxide.

In organic solvents, such as

dimethylsulfoxide, chloroform, etc., complex can be di·ssolved; however it
has been reported (8) that the complex decomposes, and the cyclodextrin
complex of the solvent is formed.

This is posible since in the complex

formation the nonpolar part of the guest molecule penetrates into the
nonpolar cyclodextrin cavity, thereby establishing an energetically
favorable nonpolar-nonpolar interaction .

When an organic solvent is used

to dissolve the complex, if the solvent is more polar than the included
guest molecule, then a complex with the organic solvent will be formed.
In this study, since the phenytoin beta-cyclodextrin complex did not
dissolve in the deuterium oxide, it was very diffcult to show the complex
formation in the liquid phase .

However, the phenobarbitone complex

readily dissolved in the deuterium oxide, and the results are shown in
Fig. 23 .

The large peak at approximately 4.6ppm is common to both

spectra due to small amounts of deuterium hydroxide and water as
impurities.

All the peaks observed in the Fig. 23a, are those of the

beta-cyclodextrin .

The deuterium oxide peak is fixed in both spectra;

this peak was used as an internal standard for the comparison of the
chemical shift observations.

From the spectra of both the

beta-cyclodextrin and the complex, it is clear that all of the protons of
the complex located in the internal cavity of the beta-cyclodextrin are
experiencing a shielding effect; hence signals are shifted upfield (Fig .
23b).

These spectra strongly suggest the presence of the complex in the

liquid phase.
Demarco and Thakkar (52) reported

~hat

the protons l ocated in the

interior cavity of the beta-cyclodextrin (C - 3-H, and C-5-H) will be
considerably shielded by the guest molecule; hence the signals will be
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shifted upfield.

Whereas, the protons on the outer surface (C-2-H,

C-4-H, and C-6-H) will not be affected by the guest molecule; hence the
signals of those protons will remain unchanged.

In addition, Frank and

Cho (32) also observed similar results in the study of the complexing
behavior of dinoprostone with beta-cyclodextrin in water.
h. Photomicrographs
Figures

24, 25 and 26 show the morphology of recrystallized

beta-cyclodextrin, phenytoin, and phenobarbitone before and after freeze
drying .

All the photomicrographs were taken at the same magnification

(125x) .

As shown in the Fig. 24a, the beta-cyclodextrin is a crysatlline

material, however after freeze drying it has completely transfonTied into
an amorphous state.

This amorphous state is also confinTied in the X-ray

analysis (Fig. 14b). Whereas phenytoin and phenobarbitone ( Figs.
26b) as seen i n the X-ra y analysis (Figs .

25b and

14a, and 15b) did not

transfonTI into an amorphous state, the complex prepared by the freeze
drying method of these two drugs as shown in Figs .
completely transfonTied into an amorphous state.
observed in the X-ray analysis (Figs .

27b, and 28b, are

This was also previously

13c, and 15c).

prepared by various methods are shown in Figs.

The complex

27a, 28a, and 29.

It is

very diffcult to prove in an unambiguous manner the fonTiation of an
inclusio n complex in these photomicrographs; it can be readily shown in
Fig. 29b that, some kind of interaction has taken place in the complex
prepared by the solvent evaporation method.

As previously discussed, a

single crystal isolated from this preparat io n was taken for lattice
parameters measurement and showed an increase in one of the axial length.
The results are reported in the Table (XIV) .

Based on this

photomicrograph, the lattice parameters data, and also from the X-ray
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Fig . 24a:

RECRYSTALLIZED BETA- CYCLODEXTRHI AT l 25x.
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Fig. 24b:

FREEZE DRIED BETA- CYCLODEXTRrn AT l25x.
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Fig. 25a:

PHENYTO!N AT 125x .
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Fig. 26a:

PhENOBARBITON E AT 125x.
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Fig. 27b :
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SOLVENT EVAPORATED PHENYTOIN COMPLEX AT 125x.
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diffractogram, it is conceivable that inclusion complex may be present in
the solvent evaporated material.
B.

Preparation of the complexes
a. Solvent evaporation
Solvent evaporation is a simple method however, it is a costly and

time consuming procedure because:
(i) .

The solvent of a small batch size of 200ml requires at least 10-12

days to evaporate at room temperature.
(ii) .

The solvent is 50% ethanol, which is expensive and without a

solvent recovery system this process may not be economically feasible.
A phenytoin beta-cyclodextrin complex was prepared by this procedure
with a satisfactory yield of 95%.
crystalline form.

(

The final end product was in a

As discussed in Section !!IA, d., th e measurement of

lattice parameters showed some interaction with the beta - cyclodextrin.
However, in order to collect a reasonable quantity of material to begin
formulation work, it would take several months' time to collect a
workable amount of material.

Further, even in the lite rature this method

of preparation of inclusion compounds has not been explored.
b. Kneading
In the preparati on of inclusion compounds the most common techinque
is to stir or shake an aqueous solution of cyclodextrin with a guest
molecule or its solution.

In aqueous solution the apolar cyclodextrin

cavity is occupied by water molecules that are in an energetically
unfavorable state (polar - apolar repulsion) and are, therefore readily
replaced by an appropriate guest molecule that is less polar than water
(Fig. 4).

In this kneading process the cyclodextrin is not dissolved, it

is kneaded with a small amo un t of water to make a slurry, and then guest
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components are added to the slurry of

cyclodextrin.

Since neither the

guest nor host molecules are dispersed at a molecular level, it is
difficult to conceive the formation of inclusion compounds in this
process.

However, this method of preparation has been reported in the

literature (8).
A phenytoin-beta-cyclodextrin complex was prepared by this method
with a satisfactory yield of 92% .

Only the X-ray-analysis (Fig. 14 ) ,

showed ambiguously the presence of the inclusion complex as a separate
molecular species.

Thus, it is interesting to see the effect of kneaded

complex on formulations.
c . Spray drying
Figs. 27a and 28a show the morphology of spray dried phenytoin and
phenobarbitone complex with beta -c yclodextrin .

It appears from the

photomicrographs that the complex may be a physical mixture of the pure
components (Figs. 24a, 25a and 26a).

These types of results may be

conceivable from the spray drying process as follows.
During the spray drying process the surface liquid is quickly
evaporated and a tough shell of solids may form in its place.

As drying

proceeds, the liquid in the interior of the droplet must diffuse through
this shell;

however, the diffusion of the liquid occurs at a much slower

rate than does the transfer of heat through the shell to the interior of
the droplet.

The resultant build-up of heat causes the liquid below the

shell to evaporate at a far greater rate than it can diffuse to the
surface.

The internal pressure causes the droplet to swell; and if the

shell is nonelastic, it ruptures, producing either fragments or ruptured
hollow spheres and perhaps some intact spheres .

Therefore, when the

cyclodextrin solution with the drug is sprayed, if the shell is
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nonelastic, it may rupture producing fragments of drug and cyclodextrin
or there may be fragments of both species together.

Hence, if the shells

of cyclodextrin solids are nonelastic it may not be possible to produce
an intact cyclodextrin species containing drug molecules.
As shown in Figs. 14 and 15, only the X-ray analysis showed some
kind of interaction with beta-cyclodextrin rather than a physical mixture
of the pure components.

The photomicrographic evaluations are highly

subjective; therefore based on the X-ray analysis, it is felt that the
inclusion complex exists as a separate molecular species.
However, there was only a 10% yield of the complex prepared by this
method.

The low yield is due to the poor design of the equipment rather

than technique, because of the following reasons:
The solution was sprayed as fine droplets into a moving stream of

(i).

hot

air, where they did not evaporate rapidly before reaching

the wall of

the drying chamber.

The resultant build-up of liquid droplets on the wall of the

(ii).

drying

chamber did not dry into a fine powder to give a good

yield.
(iii).

The temperature of the system was fluctuating constantly during
the

(iv)

spraying process.

The peristaltic feed pump was not functioning properly.
Therefore, because of the unsatisfactory yield,, this method was not

explored further.
d. Freeze-drying
Among the various methods of preparing the inclusion complexes, this
method was satisfactory at a laboratory level.

However, the ampicillin

inclusion compound could not be prepared by this method since it has been
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(114) reported that the rate of decomposition of the ampicillin increases
upon freezing.

Savello and Shangraw (139) showed that for a 1% sodium

ampicillin solution in 5% dextrose, the percentage of degradation at four
hours is approximately 14% at -20°c, compared to 10% at

s0 c.

Therefore,

only phenytoin and phenobarbitone beta-cyclodextrin complexes were
prepared firstly by using a laboratory freeze drier.
As shown in Fig. 13c, the phenytoin beta-cyclodextrin complex
prepared by the freeze drying method strongly suggested the presence of
inclusion complex as a separate molecular species .

In addition the OSC

thermograms (Fig. 17) also suggested that the freeze dried complex is not
a physical mixture.

Similarly, the DSC thermograms of the phenobarbitone

complex (Figs . 19 and 20) and the NMR spectra (Fig. 23) strongly
indicated the presence of the inclusion complex in solid phase as well as
in liquid phase.
Although there are different methods of preparing the inclusion
complexes, they are not suitable at the pilot scale or manufacturing
level.

Kurozumi

~

(51) prepared the inclusion compounds of

non-steroidal antiinflammatory and other slightly soluble drugs with
alpha and beta - cyclodextrins.

They reported that the freeze-drying

method was successful in obtaining the inclusion compounds of all the
test drugs.

However, they did not describe how such inclusion compounds

can be produced at the pilot scale or manufacturing level.

Similarly

Lach and Cohen (40) studied the interaction of nineteen compounds with
cyclodextrins, but they did not report how to harvest these inclusion
compounds.
In the present study, preparation of the inclusion compounds using
the freeze drying method is expanded from a laboratory freeze drier to an
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industrial level freeze-drier.

Since the laboratory freeze drier was not

capable of handling more than a liter per batch, the batch size was
limited to one liter.
4-5 days.

The total time required to comp lete the batch was

Although theoretically the yield per batch (with 2% solids)

was 20 grams, the experimental yield was only 18 grams.

Therefore, in

order to begin formulation work by using the laboratory freeze dryer it
would take months to collect a reasonable quantity of material.

Hence,

the success of a new drug or complex for dosage forms formulation work is
dependent upon scale-up evaluation from laboratory procedure to routine
production operations.
With this in mind two phenytoin beta-cyclodextrin complex batches
were made using an industrial level freeze dr yer at Miles Pharamceutics
in West Haven, Connecticut .

The first batch yield (Ta ble XVI) was much

poorer than expected (43% less).

This process was carried out in an open

tray freeze - drying system under a vacuum, thus, directly exposing the
drying material to the applied vacuum.

A large portion of the dried

fluffy end product may have been inadvertently vacuumed away during the
drying cycle.

In order to increase the yield and decrease the percent

loss, another batch was made with a minor modification to the open tray
system (Fig . 30a).

As shown in the Fig. 30b, a cover with an opening in

the cente r was placed onto the open metal tray.

In addition, a stainless

steel screen (30 mesh) was used to cover the center opening (Fig. 30c).
This equipment resulted in a reduction in direct exposure and prevented
the loss of the drying material to the applied vacuum.

The yield was

significantly improved, limiting the loss to 27% (Table XVI) .
The results of preliminary scale-up batches indicated that the
preparation of the complex by freeze drying may be scaled-up to a
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Table XVI
Preliminary scale-up results of the phenytion beta-cyc lode xt rin comp l ex.

Batch No .

Batch size
(liters )

2

Yield obtained
(gms. )

Yie l d expected
(gms )

%

Loss

10

113

198

43

B

116

158

27
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manufacturing level.

In addition moisture content determinations of the

comple x and the drug content analysis (Table XVII) suggested that the
method is also reproducible.

It was felt that it may be possible to

improve the yield by using finer screens to cover the center opening in
Fig. 30b.

A 60 mesh stainless steel screen over the center openi ng

improved the yield from 73% to 90% (Table XVIII).

Thus, it was clearly

shown that th e preparation of the phenytoin inclusion compound can be
scaled-up to manufacturing level.

The total length of time required to

complete the ten liters batch was little less than two days (Appendix B,
1), compared to four to five days to complete the lite r batch by using
the laboratory freeze drier.

In addition, in the laboratory freeze

drier, it was not possible to determine the final end product temperature
without breaking the vacuum system.

However, as shown in Appendix B, 1,

it was possible to determine quantitatively the final end product
temperature.
A phenobarbitone beta-cyclodextrin complex was also prepared using
the same technique to improve the yield.
of more than 90%.

It was possible to get a yield

The total length of time required to complete the ten

liter batch was less than two days (Appendix B, 2).
C.

Preparation and evaluation of dosag e forms
1.

Liquid dosage forms

The compositions of two potential liquid formulations are given in
Tables IV and V.

These preparations were visually examined for clarity,

( precipitation, crystal growth) change in color, odor, etc.

After two

weeks the formulation containing 10% glycerol, 40% sorbitol, and 20%
syrup (Table V) showed slight precipitation and microbial growth.
However, the formulation (Table IV) containing 40% glycerol, 20% sorbitol
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Table XVII
Some properties of the phenytion beta -cyclodextrin complex.

Batch No

2

Batch size

Moisture content

% Drug content

10

6.50

18 . 90

8

5.70

18.30
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Table XVIII
Scale-up results of the phenyt oin beta-cylcodextrin comple x.

Batch no.

Batch size
( liters )

Yield obtained

% Yield

(gms. )

10

113

57

2

8

116

73

3

10

160

80

4

10

160

80

10

180

90

123
and 20% syrup did not show any precipitation or visual evidence of
microbial growth after samples had been stored at ambient temperature up
to four months.

The probable reason for an increase in stability of the

formulation is the higher concentration of glycerol, since glycerol
itself acts as a preservative when it is present in higher concentrations
(130).

This formulation was compared with an official elixir ( 128 ) with

respect to physical properties as well as one month's chemical stability
data.

The results are in Table XIX.

glycerol, 15% syrup and 15% alcohol.

The official formula contains 45%
The alcohol content of the official

preparation is required to keep the phenobarbitone in solution; however,
the alcohol content in the official elixir may not be desirable,
especially for pediatric use.

For the phenobarbitone beta-cyclodextrin

complex the addition of alcohol was not required.

It has been reported

(140,141) that in the case of elixir of phenobarbitone, propylene glycol,
and a combination of poly- alcohols can be used as substitutes, and
formulations using these substitutes have been proposed.

Peterson and

Hepponen (142) , developed a formula containing 35% of propylene glycol,
20% syrup, and 0.4% of phenobarbitone with 0.1% flavoring oil .

They did

not report any chemical stability data, however, after three months
physical stability was satisfacto ry.

In or der to aid in masking the

bitter taste of phenobarbitone, and since propylene glycol does not add
any sweetness as does the glycerol of the official formula , they
increased the syrup content from the 15% of the official formula to 20%.
However, their taste tests showed that the propylene glycol preparati ons
were less acceptable than the official elixir.
The formulation (Table IV) of the present study does not contain any
propylene glycol, and the concentration of the glycerol is similar to
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Table XIX
One month chemical stability of solution prepared from the phenobarbitone
beta-cyclodextrin complex, stored at room temperature.

Product

% Label claim *

Fonnulation #1 (Table IV)

94.80

Official elixir**

97 .60

* An average of three injections.
** Contains 45% glycerol, 15% syrup, 15% alcohol, and 0.4%
phenobarbitone .
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that of the official preparation.
the official formulation.

The taste was better than or equal to

Furthermore, it is the op in ion of the author

of this thesis that the complex could readily be used as a powder for
reconstitution were any chemical stability problems to arise in the
preparaticrn.
A phenytoin suspension was prepared (Ta ble VI) from t he complex and
its physical stability up to two years did not show changes in
appearance, color, odor, etc.

The results of the sedimentation study

{Fig. 31), indicated that the sedimentation volume was slowly decreased
during the first period of the week, then decreased grad ua lly .

However,

even after six months, the sedimentation volume was approximately 60% of
its original value.

The redispersibility study showed that ten

revolutions were required to restore the suspension to homogene ity.
blender rotation was 20 to 22 rpm.
redispersed within 30 seconds .

The

Hence, the suspension was easi ly

In order to compare the ease of

redispersability using the tech nique described in Experimental Section
Ile, 2c, a light magnesium oxide suspension was introduced as a control.
The percentage of solid content was the same as in the phenytoin
suspension (Table VI) in the same suspending medium.

However, due to

formation of a concrete cake, it was not possible to redisperse the lig ht
magnesium oxide suspension, even after five minutes.

In contrast, the

phenytoin beta-cyclodextrin complex suspension, which contained amorphous
freeze dried material, formed a flocculated suspension.

A floe, or

floccule, by definition (143), is a loose aggregation of individual
particles that are held together by comparatively weak
particle-to-particle bonding forces; the sediment is loosely packed
has a scaffold - like structure.

Particles do not bond tightly to each

and
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Sedimentation study of th e suspension prepared from the
phenytoin beta -cyclodextrin comp lex.
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other, and a hard, concrete cake does not form.

The sediment of our

suspension was easy to redisperse, so as to form the original suspension.
Generally, a typical suspension form ula contains drug, suspending
agent, suspending medium, flocculating agent, electrolytes,
preservatives, etc . (144 ,145 ).

But the formula selected in this study

(Table VI ) contains only drug or suspensoid and suspending medium.

It

may also be noteworthy that a 50:50 mixtu re of water and glycerol as the
suspending medium was chosen because of the poor solubility of phenytoin
(138 ,146) plus the low solubility of beta - cyclodextrin in the suspending
medium (147).

The drug complex exhibits a minimum degree of solubility

and thereby it is possible to achieve a maximum chemical stability.
Hence, despite the high concentration of the solid content (10%) without
any extra additives, the suspension possessed desirable qualities (144,
145 and 148) such as ease of dispersion, high sediment volume, etc.
These properties are indicative of a pharmaceutically elegant suspension.
Furthermo re, the suspension was stored in a freezer (a pp. - 15°C) for a
week.

Since the freezing point of a 50:50 mixture of water and glycerol

is -22.0°c (1 4g), the suspension did not freeze at all.

This property is

another of the desirable qualities of a pharmaceutically elegant
suspension.

Figures 32, 33 and 34 depict the morphology of the

suspension stored at freezing station, refrigerator and at ambient
conditions.

As expected, it is evident from Fig. 32 that the suspension

stored at freezing temperatures showed a slight increase in particle
size, whereas Figs . .33 and 34 showed little or no change in the particle
size.

It is the author's opinion that one week storage at freezing

co nditions is too severe, hence some change in particle size is to be
expected.

The photomicroscopic technique is one of the oldest and most
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Fig . 32:

Photomicrograph of th e suspens io n stored dt

-ts0 c

( 125x )
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Fig. 3'.3:

Photomicrograph of the suspension stored at

( l 2Sx ).

5-s 0 c

130

Fig. 34 :

Photomicrograph of the suspension stored at room
tempera tu re.
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useful for detecting changes in particle s ize and crystal form.

Nash

(145) also used a similar technique in the evaluation of physical
stability of a suspension and also particle size measurement.

However,

he reported that particle size measurement using a photomicrograph gives
an approximation but not an accurate value.

Therefore Nash (145)

suggested the use of a Coulter Counter, an electronic particle counter
that measures the resistance caused by the presence of a particle in an
electrolyte.

Since it was not possible to use

such an electronic

particle counter, an estimation of the particle size was determined from
Fig. 32 .

An average of length of 25 particles was less than 25u.

Another, distinct advantage is that, since this suspension contains
freeze dried material, it is presented to the body in fine particles just
like micronized particles ready for dissolution process immediately upon
administration (150) .

In addition, the suspension is less viscous and it

was possible to pass 5ml of the suspension through a 22-gauge needle
without a great difficulty.

Hence, it may be possible to use the

suspension for intramuscular administration.
Anderson, F.M.

~

(59), reported that the bioavailability of

femoxentine beta-cyclodextrin complex, formulated as a suspension, was
found to be similar to that observed from a sugar-coated tablet of
femoxetine salt.

Their study would have been more meangingful if the

bioavailability results had been compared with femoxetine suspension
instead of its salt form.

However, it was shown in their study that the

salt form of femoxetine is equivalent to the inclusion complex of
femoxetine.

132
2.

So 1id dosage forms

As discussed in Section G (Technical aspects) of the Introduction
portion of this thesis when a formulator is called on to develop a
suitable dosage form for a new drug, he or she would likely first
consider solid dosage forms, due to several reasons, mainly:
a.

Formulation and stability problems arise less frequently with solid

dosage forms than with liquid pharmaceutical preparations (130).
b.

Solid dosage forms are preferred because of their ease of

administration, dose uniformity, etc .
When a formulator faces the problem of getting a sufficient quantity

of active ingredients, an innovative modification of techniques to a
semi-micro scale.- may well be needed.

One of the most important

considerations in solid dosage forms manufacture is a uniform flow rate
of solid mixtures.

Modern high speed tabletting or capsule-filling

machines are capable of producing thousands of units per minute.
an acceptable flow of solid mixtures is essential.

Thus,

Among the various

methods used {151) to predict powder flow, various flowmeters have
received considerable attention {135,136,152-155).

These methods are

useful if sufficient quantities of active ingredients are available.
However, when a formulator faces the problem of getting a sufficient
quantity of active ingredient, then the question becomes one of
predicting the effect of formulation and processing variables on
production scale quantities using a small quantity of material.

In order

to answer this question, miniturization of flow studies was undertaken
and results are given in Table XX.
It is evident in Table XX that good flow rate and a high linearity
index were recorded through hoppers I and II as the mass was increased up

Table XX - Comparisions of mass flow ratesa with linearity valuesb

Ho
Dicalcium

l ow rate

phosphate

(Range)

er I.£

flo

Ho er III~

er I I~

Linearity Flow rate

Linearity Flow rate

linearity

(Range)

(Range)

di hydrate,

--------

--------------------- --------------------- ------------

100

49.7 (5.0)

19.0

200

162.9 (27.6)

17.7

83.1 (6.80)

17.5

43.7 (1.9)

18.1

300

177.8 (11.0)

18.2

85.2 (4.60)

19.5

40.4 (3.3)

16.7

400

202.8 (10.0)

19.1

89.7 (5.50)

19.6

600

206.7 (13.8)

19.5

95.7 (6.40)

19.7

800

201. 5 ( 5. 30)

19.6

95.5 (4.60)

19.6

1000

203.9 (8.00)

19.5

91.9 (1.70)

19.2

b (r 2 - 0.8) x 100; 1- Stainless stee l hopper from
11
Stokes si ngle punch tablet pre ss.
- Conical glass funnel . III_ Cylindrical glass funnel.

ag/s (An average of three trial s ).

w

w
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to 60% of the hopper capacity.

However, the flow rate and linearity

index were decreased through hopper III as the mass was increased from 30
to 100% of the hopper capacity.

Furthermore, effects of different levels

of lubricant on flow rates were determined with a constant mass (200gm).
The results are plotted in Fig. 35.

It is evident that lower

concentrations of magnesium stearate {0.3 and 0.6%) resulted in
increasing flow rates from all three hoppers whereas, higher
concentrations of lubricant levels (1.0 to 5.0%) resulted in a linear and
faster decrease in flow rates with larger orifice diameter (hopper I)
compared with the smaller orifice diameters {hoppers II and Ill).

Since

the three ho ppers are different in geometry and in size, variation in
flow rate was to be expected.

However, the results indicate that

although different hoppers affect the quantitative nature of the results,
the same general trends are apparent.

Hence, this study indicates that

it may be possible to use a recording powder flowmeter with small
quantities of material in an attempt to predict the flow rate, effect of
formulation and processing variables on production scale quantities.

In

addition, for routine quality control or in - process powder flow testing
situations, using a small quantity of material is cost effective .

This

makes the recording powder flowmeter data useful in numerous quality
control and in-process powder flow testing situations .

The

reproducibility and sensitivity of recording powder fl owmeter data for a
number of systems are well documented in the the literature ( 152-155 ) .
As also mentioned in Section G (Technical aspects ) of the
Introduction to this thesis, cyclodextrins are expensive f or large scale
use.

Table XX! shows some physical properties of beta-c ycl odextrin .

has reasonably good glow rate and compresssibility.

It

However, as shown in
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Table XX!
Some physical properties of the beta - cyclodextrin

Particle size distribution
(in microns)

0 - 74

11.80

74 - 125

25.70

125 - 149

32 . 00

149 - 177

15 . 00

177 - 250

12 . 20

250 - 420

3.10

Flow rate

Bu 1k density

Tap density

gm/sec

gm/cc

gm/cc

3.2

0.54

0.68

All the above values are an average of three trials.

Compressibility
%

20.58
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Table XX!!, the phenytoin beta-cyclodextrin complex prepared by various
methods does not have either good flow or comp ressibili ty properties.
Without a good flow it is very difficult if not impossible, to devel op
solid dosage forms .
day.

The usual dose of phenytoin is lOOmg three times a

Thus, based on the concentration of phenytoin (2 0%) in the complex,

it is estimated that the total amount of the complex required would be
SOOmg (equivalent to lOOmg phenytoin).

Therefore, the complex would

contribute a major portion of the t otal tablet weight.
In order to enhance the flow properties especially of the freeze
dried complex (poor flow, Table XX!!), different concentrations of the
complex were mixed with a direct compression vehicle ( Emcompress ) and
flow rates evaluated.

As the concentrati on of the complex was increased

(Fig . 36), flow rate decreased drastically .

An acceptable flow rate was

found only when the conentration of complex was less than 5%.

Thus,

direct compression was not found to be feasible, since the final tablet
weight would be more than a few

grams.

An attempt was made to prepare

slugs, however, due to lack of compressibility and flowability of the
complex, slugs could not be prepared.
method available for tabletting.

Thus wet granulation was the only

Since freeze dried materials are

generally highly soluble, it was thought that after addition of a
granulating agent the material might agglomerate rap idly;

however, no

agglomeration problem was observed during the wet granulation process.
It was then possible to develop a formula (Table VII) with an acceptable
weight and size.

It has been reported by Szejtli, J. (8) , who is one of

the authorities in the field of cyclodextrin inclusion complexes that,
"if the required dose amounts to several hundred milligrams, then
especially with low molecular weight drugs, it would be necessary to
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Table XX!!
Some physical prperties of the phenytoin beta-cyclodextrin complex
prepared by the various methods.

omplex prepared by

Fl ow
Rate mg/s

Bulk

Tap

mg/cc

mg/cc

Compressibility
%

----------------------------------------------------------------------!Freeze drying

33

65

167

61.08

302

402

744

45.97

Kneading

1836

480

727

33 .98

~olvent evaporation

3270

512

717

28.60

Emcompress*

4666

733

916

19.98

~pray

drying

* Used as a reference standard.
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Fig. 36:

Flow study of the freeze dried phen ytoin beta-c yc lo dextr i n
complex.
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disperse several grams of cyclodextrin complex tablets.

Thus no

practical application of the complex seems to be likely."

However, the

phenytoin dose is lOOmg, ( by complexation with beta-cyclodextrin) and
using the wet granulation method it was possible to make a tablet of
625mg containing lOOmg phenytoin.

It is in the opinion of the author of

this thesis that if the drug content in the complex is less than 10%, and
if the molecular weight of the drug is very low, practical application of
cyclodextrin complexes for tabletting is highly unlikel y.
Table XX!!! shows the particle size distribution, bulk properties,
flow characteristic and compressibility of formulation prepared from the
phenytoin beta-cyclodextrin complex.

The complex was prepared by the

freeze drying method and then wet granulated .

By wet granulati on it was

possible to achieve good flow rate and compressibility.

Furthermore,

tablets were compressed using an instrumented tablet press and Fig. 37
depicts the results of compressibility.

It is evident from Fig. 37 that

there is almost a linear relationship between hardness and compression
force, th us there was no problem during the compression.

Tablets were

examined for a variety of properties including weight variation,
hardness, disintegration time, etc.
properties.

Table XX!V lists all of these

All the examined properties meet the USP standards.

Fig. 38

shows the dissolution test data performed on weighed portions of the
tablets; the figure shows that at 60 minutes more than 90% of the drug
had dissolved.

Fig. 39 depicts the dissolution test data performed in

accordance with the USP monograph dissolution medium .

In this plot (Fig.

39) the dotted line represents the percent drug dissolved based on the
equilibrium solubility of phenytoin (138).

The dissolution results of

three different products are shown in this plot.

The three products are:
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Table XX!! !
Some physical properties of granulation prepared fr om the phenyto in
beta-cyclodextrin complex .

Particle size distribution
(in microns)

0 - 74

24 . 25

74 - 125

8. 75

125 - 149

6. 24

149 - 177

3.54

177

250

7.75

250 - 420

48 . 75

/

!Flow rate

Bulk density

gm/ s

gm/c c

7.0

0.5 1

~11

Tap density
gm /cc

0. 68

the above values are an average of three trials.

Com pressibility
%

25
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Comp ress io n study of th e formulation prepared from
the freez e dried phe nytoin be ta - cyclodextr i n comp l ex.

Some physical properties of the tablets prepared from th e phenytoin
beta - cyclodextrin complex .

Weight variation
(mg)
335
333
322
335
321
334
334
324
324
323
325
327
325
325
323
320
322
326
325
320

Hardness
(kg}
7.5
6. 5
9.0
8.5
7. 0
7.5
8.0
7.5
6.5
6.5
7.0
7.5
8.0
7.5
7.0
7.0
6.5
7.0
7.0
7.5

Mean 326
7.33
* (5 .0 }
(0 .67 }
*-Standard deviation

Thickness
(i nches)
0. 187
0.188
0. 188
0.187
0.190
0.1 87
0.187
0.187
0.187
0.187
0.188
0.186
0. 188
0.188
0.187
0.191
0.188
0. 188
0. 180
0.190
0.188
(0.001}

Friability
%

Disintegration
time (mintues)
7.0
6.5
5.0
5.5
4.0
6.0

0.18

5.7
( l. l )
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Dissolutio n studies of the ph enytoin beta-cyclo dextrin
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Each po i nt is an average of three determinat io ns.
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tablets prepared from the freeze dried beta - cyclodextrin complex;
Infatabs from Parke-Davis; and phenytoin tablets prepared by Mr. S.R.
Ghanta (gra duate student).

It is evident that the phenytoin

beta-cyclodextrin complex showed highest percent dissolved (more than 60%
at 30 minutes).

Because of

th~

low aqueous solubility of phenytoin

(138), dissolution was conducted with half tablets.

However, as shown in

the same plot (Fig. 39), there was no significant improvement in the
dissolution rate in water.

The tablets prepared from the freeze dried

complex reached the equilibrium solubility within fifteen minutes;
whereas, the other two phenytoin products did not reach the equilibrium
solubility even after 60 minutes.

Further, it was thought that, since

the Infatabs are used as chewable tablets, they may erode very slowly and
for this reason showed slowest dissolution rate.

However, the

instructions on the Infatabs bottle indicate that the tablets can be
either chewed thoroughly before being swallowed or swallowed whole.
Therefore these tablets were taken for comparison .

Generally, chewable

tablets are hard, they erode very slowly in the mouth, so that a slow
dissolution rate is expected.

However, when these tablets were crushed,

passed through 60 mesh sieve and filled into capsules, then dissoltuion
was compared (Fig. 40) with the similar preparation of the tablets
prepared from the freeze dried complex.

As shown in Fig. 40, the freeze

dried complex showed significant improvement in the percent drug
dissolved.

Figure 41 shows the dissolution of phenytoin

beta-cyclodextrin complex tablets after two years' storage at ambient
temperatures, compared with a sodium phenytoin capsule (Zenith Labs).
Tablets from the freeze dried complex reached the equilibrium solubility
within 30 minutes.

As shown in Fig. 41, the half tablets showed

147

120

MEDIUM- WATER
VO LUME- 900ML
METHOD- USP BASKET
AGITATION- SORPM

e - CAPS FROM FD COMPLEX
0- CAPS FROM IN FATABS

100

80
::::

LU

>
_.

0

"'"'
Q
~

60

.
::::>
c:::;
0

40

20

0

15

30

45

60

TIME (MINS)
Fig. 40:

*

Dissolution studies of the phenytoin beta-cyclo dextr in
systems.
Each point is an average of three determinat io ns.

148

MED IUM- PHOSPATE BUFFER (PH 7.4 )
VO LUME- 900ML
METHOD- USP BASKET
AGITATION- SORPM

100

80

Q
u.J

>

....J

::;;; 60
V>

Q

.'"'
:::0

c::
Q

<J- TABS FROM FD COMPLEX
~-

40

Q -

SODIUM OPH CAPS
HALF TASS FROi•I FD
COMPLEX

20

0
15

30

45

60

TIME (MINS )
Fig. 41:

Dissolutio n studies of the phenytoin beta -cycl odextri n
sys t erns .
* Each point is an average of three determinat i ons.

149
significant improvement in the dissolution rate compared to sodium
phenytoin capsules.
Dissolution was also investigated in an acidic medium.
are depicted in Fig . 42.

The results

In this plot, dissolution results of sodium

phenytoin, freeze dried complex, physical mixture of phenytoin
beta--cyclodextrin, and phenytoin powder alone are shown.

As expected,

the physical mixture and phenytoin did not improve dissolution .

However,

the dissolution rate of the complex and sodium phenytoin powder was by
and large equal after a 30 minutes time period.

Figure 43 shows the

dissolution results of the freeze dried complex tablet (full and half)
and sodium phenytoin capsule.

As observed in Fig. 42, approximately 60%

of the drug was dissolved from the complex within 60 minutes.

The sodium

phenytoin capsule showed a higher percent dissolution (apprx. 70%) within
60 minutes.

This increase in percent dissolved may be due to the effect

of formulation and processing.

However, the percent drug dissolved from

the half tablets was higher at the 30 minute time period than sodium
phenytoin capsule.

These results indicated that even in the acidic

medium the dissolution of the phenytoin beta-cyclodextrin complex was
better or equal to the sodium phenytoin capsules.
Since there was no sig nif icant difference between total percent drug
dissolved in water and in an acidic medium, further dissolution work was
carried out in water according to the USP (128) .

Figure 44 shows the

dissolution results of phenytoin beta-cyclodextrin complex prepared by
the various methods.

As indicated earlier the dotted line represents the

equilibrium solubility of phenytoin in water at 37°C .

In this plot the

complex prepared by spray drying, kneading, etc, showed less than 40%
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drug dissolved even at 60 minutes.

Whereas, the complex prepared by th e

freeze drying method showed more than 60% dissolv ed at 60 min utes.
This increase in percent diss olved is due to the amorphous nature of
the freeze dried complex as seen earlier in X-ray analysis ( Fig. 13c) and
photomicrographs ( 27b ) .

However as shown in Table XXV, there was no

si gnificant difference i n disintegration time of phen ytoin
beta-cyclodextrin complex t ablets prepared by the va r ious methods.
Furthermore, it was thought that a decrease in partic le size of phenytoin
may increase the dissolution rate similar to the freeze dried complex.
Hence, phenytoin was freeze dried alone, compressed into tablets and
dissolution was carried out.

The results are shown in Fig. 44.

As shown

in Fig. 44, the freeze dried phenytoin did not improve t he dissolution
rate

However, when the freeze dried phenytoi n was mixed with fre eze

dried beta-cyclodextrin, the tablets prepared from th at mixture showed
(Fig. 44 ) the similar resu lts as obta ined from th e free ze dried complex.
As shown in Fig. 44, there is a slight difference at 15 minutes time
period; however, after that time period, the percent drug dissolved was
by and large equal to the freeze dried complex.

This unique phenomenon,

may be due to the in situ complex formati on in the dissolution medium.
It is the opinion of the author of this thesis that as f ar as ca n be
ascertained, this unique phenomenon (i n situ complexation) is the first
report of the interaction of beta-cyclodextrin wi th phenytoin. ·
Phenytoin is a high melting (293°C), weakly acidic (138 , 146 ) and
poorl y water soluble drug (138).

Because of these physicochemical

properties, phen ytoiri is subject to erratic and incomp lete
bioava ila bility (156-1 59).

Phen ytoin has been classified as a drug with

"high risk potent ial " with respect to bioavailability problems (160 , 161).
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Table XXV
Disintegration time of the phenytoin beta -cyclodextrin complex tablets
Prepared by the various methods.

Mehtod of pre para ti on

Disintegration time in minute~
(Standard deviation)

Freeze drying

6.5 ( 1. 2)

Spray drying

6. 0 (2 . 3)

Kneading

7. 3 (3 .0)

Solvent evaporation

7.8 ( 2. 5)

l~

It has been reported that the rate of dissolution of phenytoin is
influenced by particle size (162) , characteristics of excipients {163),
manufacturing procedures and dosage form (164).
Chakrabarti

~

(162) reported that significant differences in

bioavailability were observed when phenytoin crystals of different
particle size were administered.

In their investigation 3 dogs were

administered 390 _: lOmg capsules in a cross-over design with an interval
of one week between two administrations.
used in the analysis of drug content .

The radioimmunoassay method was

The largest area under the curve

(AUC) and maximum concentration (Cmaxl were observed with smallest
particle size (0-32u),
respectively .

followed by 75 and lOOu

Chakrabarti

~

particle size

{162) did not report the time required

to reach maximum (Tmax l plasma level.

The paired t-test was used to show

the significant difference between the Cmax and the AUC among the
treatments.

They concluded that the AUC is inve rsely related to the

particle size.

In addition, their results were correlated with the

faster dissolution of phenytoin of smaller particle size.

It is the

opinion of the author of this thesis that since the phenytoin
beta-cyclodextrin complex prepared by the freeze drying method produced
amorphous particles (less than 25u), and therefore a smaller dose would
be enough to achieve the therapeutic range of plasma level (10- 20 ug/ml).
Yakou

~

(163) , reported the effect of manufacturing procedures

on the dissolution and human bioavailability of phenytoin.

The

dissolution characteristics of commercial phenytoin, freeze dried
phenytoin, 20% simple blend of phenytoin with lactose and starch, and 20%
solvent deposition of phenytoin powder were determined in pH 1.2 and 7.5
test media.

The results are summarized as follows:

l~

a.

The solvent deposition of phenytoin with PVP, showed the fastest

dissolution rate (app. 15% in ten minutes).

This increase in dissolution

rate is probably due to improvement in the wetability of the phenytoin
crystals as well as decrease in particle size.
b.

Based on the results of the in vitro studies, 20% phenytoin solvent

deposition powder and the phenytoin crystals were selected for a
bioavailability study in humans .

A cross-over study was carried out in

six healthy male volunteers, and 300mg of phenytoin was administered
orally.

The plasma samples were assayed for phenytoin by the method of

enzymeimmunoassay.

The urine samples were assayed for phenytoin by

gas-liquid chromatography .
c.

The commercial crystals gave a very low plasma level and showed a

significant difference was found at each time period.

The coprecipitated

powder gave 7.63-11.6 times larger AUC than the phenytoin crystals in
individual volunteers and the mean was 8.97 times larger .

The urinary

excretion study also revealed a lower excretion rate of pheyntoin from
the crystals.
d.

It was concluded from the above study that the phenytoin crystals

(between 177-350u) gave significantly lower bioavailability than the
coprecipitated powder due to poor dissolution characteristics of the
fonnulation.

However, the authors of this bioavailability study did not

report the particle size range of the coprecipitated phenytoin powder.
They simply reported that when the same batch of phenytoin crystals was
processed by solvent deposition, the particle size might have reduced in
the course of the manufacture to below the critical range ( less than 50u )
of crystal size distribution.

Further, they concluded that a
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manufacturing method affects the bioavailability of phenytoin
preparations substantially.
Sekikawa

~

(164) reported the dissolution behavior and

absorption of phenytoin and phenytoin polyvinylpyrrolidone (PVP )
coprecipitate in five male subjects.

The dissolution characteristics of

phenytoin and coprecipitated phenytoin with PVP were determined in pH 1.2
and 7. 5 test media.
a.

The results are summarized as follows:

The dissolution rate of phenytoin coprecipitate was markedly

increased (app. 31 . 50% in fifteen minutes) in the dissolution media.

The

concentrations of phenytoin following the dissolution of 1:3 or 1:5
coprecipitates were 2.3 times as much as phenytoin solubility (25ug/ml )
in the test media .

The dissolution rate of coprecipitate with PVP of

lower molecular weight was greater (K- 15
b.

K- 30

K-90) .

Based on the results of the in vitro studies, a bioavailability study

was conducted in five male subjects, and 250 mg of phenytoin was
administered orally .

A cross-over design was used .

Urine was collected

at hourly intervals for the first nine hours and at a convenient time
intervals up to 120 hours after administration.

The urine samples were

assayed for the main metabolite (5-p-hydroxyphenyl-5-phenylhydantoin ) by
a gas-liquid chromatography.
c.

Blood samples were not taken

Following the administration of the coprecipitate, the maximum value

of mean urinary excretion rate of the metabolite appeared in the 8-12
hour period.

Excretion rate of the coprecipitate was almost twice that

of the phenytoin alone in the 8-12 hour time period.

The intersubject

variation of excretion rates were considerably smaller when the
coprecipitate was administered.

The recoveries of the metabolites

excreted in urine for 120 hours following the administration of the
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coprecipitate and phenytoin alone were 84 .3% and 54 . 7% respectively .
Extent of bioavailability of phenytoin in phenytoin PVP-coprecipitate was
1.54 times greater than that of phenytoin alone .

Acco rding to the

authors of the above study, higher excretion patterns may be considered
to be a reflection of the in vitro dissolution behavior of each
preparation.

High dissoltuion rate and supersaturation of phenytoin f rom

the coprecipitate resulted in the large improvement of the rate and
extent of the bioavailability of poorly water - soluble phenytoin.
Furthermore, Yakou et al (165) also reported the particle size dependency
on dissolution rate and human bioavailability of phenytoin and phenytoin
polyethylene glycol solid dispersions.

The dissolution characteristics

of phenytoin and phenytoin solid dispersion prepared at various ratios of
polyethylene glycol 4000 were

determined in pH 1.2.

The results a-re

summarized as follows:
a.

At lower ratios of phenytoin to polyethylene glycol (0 .5:10, and

1:10) the bulk concentration reached a plateau of 43ug/ml (10 . 75%) in
less than five minutes, while higher ratios (2:10, 3:10 and 4:10) gave
rapid rises to 32ug/ml (8 . 0%) in five minutes with subsequent small
increases.
b.

These results suggested that a rati o of less t han l to 10 is required

to disperse phenytoin completely in polyethylene glycol.
c.

Further, the dissolution rate of different particle size suggested a

critical particle size between 74- 149u for higher dissolution rate.
d.

Based on the results of the in vitro studies, a bioavailability study

was conducted in five male subjects, and 300mg of phenytoin crystals
(size 44-53um), 200mg of physical mixture with polyethylene glycol, and
200mg of the solid dispersion powders were administered orally .

A
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three-way cross - over study was used.

Blood samples were taken at 2, 4,

6, 8, 12, 24, 32, 36, and 48 hour, and urine was also collected at the
same i ntervals.

The plasma samples were assayed for phenytoin by enzyme

immunoassay and the levels of the intact phenytoin in urine were assayed
by gas-liquid chromatography.
reported.

The details of the assay methods are not

Phenytoin solid dispersion gave the highest plasma level

(3.74ug/ml) in 5.6 hours, followed by the physical mixture and phenytoin
alone.

The physical mixture gave a plasmal level of (l.92ug/ml) in 6.8

hours, and phenytoin gave a lowest plasma level of 0.75ug/ml in 5. 7
hours.
e.

The areas under the plasma level curve were: phenytoin solid

dispersion 73.86h . ug/ml, phenytoin physical mixture 50.26h.ug/ml, and
phenytoin crystals 18.45h . ug/ml.

There was a significant difference

among the treatments as shown by Student 's-t-tes t.
f.

The urinary excretion rate from the solid dispersion of phenytoin in

polyethylene glycol exceeded that from the physical mixture or the
phenytoin crystal at any time.
g.

It was concluded from the above study that the phenytoin solid

dispersion showed superior dissolution and bioavailability.

These

characteristics of the phenytoin solid dispersion should offer the
clinical advantages of quick drug release and excellent bioavailability
in phenytoin therapy.
As previously mentioned in Section F, 6 (Bioavaila bility) of the
Introduction to this thesis Tsurika

~

(95) studied the absorption of

freeze dried phenytoin, phenytoin, and its beta-cyclodextrin complex in a
group of four female beagle dogs.

They reported that there was a

two-fold increase in the area under the curve of the blood level.

The

160
Student's-t-test showed a significant difference in the blood level
curves .

Jn addition, it was reported that an increase in bioavailability

of phenytoin by means of beta - cyclodextrin complexation suggested the
possibility of smaller doses and fewer side effects in phenytoin th erap y.
The results of the in vitro dissolution studies of phenytoin
obtained by Yakou

~

(163), Sekikawa et al (164), and Yakou et al

(165) can be compared with the results obtained by the author of this
thesis .

These results are summarized in Table XXVJ.

As shown in Tab le

XXVI , it is clearly evident that phenytoin beta-cycl odext rin showed
su perior in vitro dissolution results in all media .

However, direct

com parison may be questionable since dissolution results are a function
of dissolution methodology, dissolution volume, agitation speed, etc.
Despite these differences, it is in the opi ni on of the author of this
thesis that the phenytoin beta-cyclodextrin complex dissolution rate is
superior among all the preparations.

Hence, it may be possible to use a

smaller dose in in vivo studies with fewer side effects.

Furthennore,

the reported pheyntoin preparations such as solid dispersion,
coprecipitation, etc. are prepared at a laboratory scale.

The

feasibility of fonnulation and incorporation in to a suitable dosage fonn
are not explored.

Physico - chemical properties are not fully tested, and

hence direct practical application is skeptical.

However, the scale of

production of the phenytoin beta-cyclodextrin complex was increased from
a laboratory scale to an industrial scale.

Physico-chemical properties,

feasibility of fonnulation, etc. are studied in this thesis.
Anderson,~-

(59), reported a preparation of an inclusion

complex of femoxetine with beta-cyclodextrin by a precipitation method.
The method of preparation was time consuming and labo r ious (o ne liter
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Table XXV!
Comparisons of the in vitro dissolution data of the tablets prepared
from t he phenytoin beta - cyclodextrin complex with the literature data
of other phenytoin tablets preparations.
Phenytoin tablets

preparation

% Drug dissolved in different media
Time (m inutes )

pH 1.2

I*

l. So 1ve nt deposition

** 2. Coprecipitaion with PVP
'*** 3. Solid dispersion in

pH 7.5

Water

7.50 (10)

7.50 (10)

NR

31.50 ( 15)

25 . 23 ( 15)

NR

10 . 75 (5)

NR

NR

pH 7.4

Water

56 . 00 (15)

58.30 ( 15)

Polyethylene glycol
(0.5 : 10 . 0)

pH 2. 2

4. Beta - cyclodextrin complex

*-According to reference (163).
**-According to reference (164) .
***-According to reference (165) .
NR- Not Reported

53 . 50 (15)
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batch took one week to collect the precipitate and one day to dr y in
vacuum).

The yield was onl y 87% .

etc. were not reported.

Scale-up evaluations, reproducibility,

However, they had developed a suspension dosage

fonn only on a small sacle (lOOml) from the complex.

Physical properties

of the suspension such as else of dispersion, sedimentation volume,
freeze thaw study, etc., were not studied.

Hence, the fonnulation

feasibility and physical stability are to be investigated .
Sea, et al. (88), studied the inclusion complex fonnations of
spironolactone with three cyclodextrins (alpha, beta, and gamma).

They

obtained the solid complex by a precipitation method, it took seven days
to precipitate the complex and then 48-hr to dry the complex at

6o 0 c.

The percent yield, scale-up, dosage fonn development, etc., were not
reported .

It is the opinion of the author of this thesis that the method

is time consuming and also that the preparation of the solid complex of
aqueous labile drugs can be a problem .

However, the above authors did

not report any stability problems .
Iwaoka,~·

(104), studied the abs orption of phenobarbitone from

suppositories contaning beta-cyclodextrin .

They dissolved the drug and

beta-cyclodextrin in a molar ratio of 1:1 in hot water (temperature not
reported), the solution was then filtered and left to crystall i ze (l ength
of time not reported).

In this study also details of the preparation of

the complex, scale-up evaluation, etc., were not reported.

However,

after rectal administration of the suppository containing the
beta-cyclodextrin complex to rabbits, the blood concentration of the drug
was higher than that following administration of the phenobarbitone
suppository.

In the present thesis, the complex was prepared on a large

scale; a batch of ten liters took less than two days, and the yield was
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more than 90%.

It is the opinion of the author of this thesis that the

complex obtained by the freeze drying method was amorphous; hence it may
be more easily uniformly dispersed in a melted suppository base than the
crystalline complex obtained by
Tokumura,

~-

Iwaoka~-

(104).

(166), studied an inclusion complex of cinnarizine

with beta-cyclodextrin in aqueous solution and in the solid state.

They

confirmed the inclusion formation by the solubility, powder X- ray
diffractometry, differential scanning calorimetry and proton magnetic
resonance spectroscopy methods.

In order to prepare the complex,

coprecipatation and neutralization methods were used .

Scale - up

evaluation, batch size, drug content in the complex, percent yield, etc.,
were not reported.

Even though they reported that the dissolution rate

of cinnarizine in the inclusion complex was 30 times larger than that of
cinnarizine alone,

they did not report on how one can conveniently

incorporate the complex into a suitable dosage form.
The literature is replete (87, 95, 101 - 103) with papers which report
laboratory techniques of the preparation of inclusion complexes.

It has

been shown that dissolution and bioavailability of drugs improved by
complexation with beta-cyclodextrin.

However, how such inclusion

complexes can be scaled- up from a laboratory scale to a pilot scale,
formulation development, etc., have not been reported indetail.
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IV Conclusions and suggestions for future work
The following are believed to be the salient conclusions of this
work as reported and discussed in the previous section.
The data obtained in this thesis indicate that the beta - cyclodextrin
interacts with ampicillin, phenobarbitone, and phenytoin. The mode of
interaction was studied by a variety of methods, which include stability,
solubility, X- ray diffractometry, differential scanning calorimetry,
infrared and proton magnetic resonance spectroscopies, photomicrographs,
etc.

It was found that in the preparation of the complexes, the freeze

drying method was the most feasible and reproducible from a laboratory
scale to a pilot scale production.

However, because of ampicillin

insta bility under freezing conditions, it was not possible to obtain the
inclusion compound in the solid powdered form.

Phenobarbitone and

phenytoin beta - cyclodextrin complexes were prepared using both a
laboratory model freeze drier and an industrial model freeze drier.
Modifications to the techniques in the freeze drying process allowed the
yield to be improved to almost 90%.
Properties of the complexes in solutions were evaluated by
stability, solubility and proton magnetic resonance spectroscopy methods.
In addition, to confirm the presence of the inclusion complex in the
solid phase, X-ra y diffractometry and differential scanning calorimetry
techniques were found to be useful.

Infrared spectra and

photomicrographs were difficult to interpret in an unambiguous manner.
However, these two methods are deemed to be useful to some extent; hence,
they can not be ruled out in the evaluation of physico-chemical
properties of the complexes.

Liquid dosage forms were

prepared from the
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phenobarbitone and phenytoin beta-cyclodextrin complexes.

A solution

dosage form was prepared from the phenobarbitone beta-cyclodextrin
complex .

Unlike an official preparati on there was no need to use ethanol

to keep the phenobarbitone in solution.

Hence, this dosage form may hav e

a considerable potential, mainly for pediatric use.

Evaluation of the

physical stability of the suspension prepared from the phenytoin
beta-cyclodextrin complex were indicative of a pharmaceutica lly elegant
suspension .

In addition, another distinct advantage is that this

suspension contains freeze dried material so it is presented to the body
in fine particles and therefore ready for the dissolution process
immediately upon administration.
Despite the lack of flowability and compressibility of the phenytoin
beta-cyclodextrin complex, it was possible to manufacture tablets of
suitable size and weight.

All the examined physical properties of the

tablets were found to be within the USP standards.

Dissolution studies

of the tablets in different dissolution media indicated

that the

phenytoin beta-cyclodextrin had greatly improved dissolution compared to
the uncomplexed drug.

Due to in situ complexation of the physical

mixture of the freeze dried phenytoin and beta-cyclodextrin, tablets
prepared from the mixture showed a similar dissolution profile to that
obtained from tablets prepared from the complex.

However, a similar

dissolution profile was not observed from the tablets prepared from th e
nonfreeze dried phenytoin and beta-cycl odextrin.

Hence, it ma y be

concluded that, when the substrate disperses at a molecular level, it
comes in direct contact with the molecularly dispersed ligand and in situ
complexation takes place in the dissolution medium.

It appears that the

rate limiting step to form in situ complexation is the solubility of a
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substrate in the vicinity of the solution of a ligand.

In order to

increase the dissolution rate by in situ complexation, the following
techniques may be useful:
a. A physical mixture of a weakly acidic drug and cyclodextrins can be
mixed with a GRAS (Generally Recognized As Safe) buffering agent to
compress a tablet along with other tabletting ingredients.
b. When such tablets disintegrate in the dissolution medium, the
buffering agent will cause a rise in pH in the close proximity of
disintegrated tablet.

When there is an increase in pH, a weakly acidic

drug will dissolve an·d may fonn an in situ complex with the molecularly
dispersed cyclodextrins .

This technique makes it possible to increase

the dissolution rate of weakly acidic drugs.

However, there are some

assumptions to be made to make this technique work.

Firstly, weak ly

acidic drugs are stable in the presence of a buffering agent in the
liquid as well as solid phase .

Secondly, the amount of a buffering agent

incorporated is sufficient to increase the pH in the dissolution medium
so as to increase the solubility of weakly acidic drugs .

Furthennore,

due to an increase in the pH, acidic drugs will ionize (depending on pKa )
and the ionized species may not fonn a complex of suitable stability
constant unlike unionized species .

A similar technique may also be

useful for basic drugs with appropriate buffering agents .
In addition, the following suggestions can be given for future work.
1.

It would be interesting to investigate the interaction of an

ampicillin with gamma-cyclodextrin, provided the cost is reasonable.
2.

Under controlled humidity and temperature facilities, micronization

or co- grinding of ampicillin with cyclodextrins might be explored to
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well as solid phase.
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due to an increase in the pH, acidic drugs will ionize (depending on pKa )
and the ionized species may not fonn a complex of suitable stability
constant unlike unionized species .

A similar technique may also be
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obtain the inclusion compound in solid powdered form, with subsequent
evaluations of the physico-chemical properties of the complex.
3.

It is planned to conduct bioavailability studies of dosage forms

prepared from the phenytoin beta-cyclodextrin complex in humans.
However, because of today's myriad regulations, the dosage forms
manufactured at URI (U niversity of Rhode Island

in the Department of

Pharmaceutics facility cannot be used for testing in humans.
(Food and Drug Administration ) requires

The FDA

brief statements that identify

the place where the drug is manufactured and tested, an outline of the
methods and facilities used in the manufacture, etc . , and these
regulations requirements can not be met at URI.

Hence, it is decided to

manufacutre and conduct bioavailability studies of the dosage forms in
appropriate (FDA approved) facilities, firstly in healthy humans (at
least six) then in epileptic patients.
4.

At present, even though cyclodextrins are somewhat expensive for

large scale use, because of their monumental potential in various fields,
in the future cost of the cyclodextrins may well become more reasonable
for pharmaceutical purposes .

Hence, it would be interesting to study the

interaction of alpha and gamma-cyclodextrins with other pharmaceuticals
to improve their physico- chemical properties such as, stability,
solubility, dissolution, etc.
5.

Furthermore, since the aqueous solubility of alpha and

gamma-cyclodextrins is higher than for the beta - cyclodextrin, the
complexes prepared from them may be useful for parenteral dosage forms.
6.

Although the literature reports the existence of delta, epsilon, and

further homologues of cyclodex t rins containing 9- 12 glycopyranose units,
they are not available commercially in the pure form. However, even if

l6i
they become available in the future, complex formation will tend to
diminish as the higher homologues of cyclodextrins increase in internal
diameter.

The probable reasons are as follows: The number of water

molecules taken up by alpha, beta, and gamma cyclodextrins are 6, 11, and
17, respectively.

As the cyclodextrins' cavity is enlarged (wit h higher

homologues), the properties of the water filling it will approach those
of bulk water .

Hence, the lowering of the energy of the entrapped water

may account for the failure of the inclusion; alternatively, the
inclusion "fit" may be too "loose".
7.

Recently, the chemically modified cyclodextrins have received

considerable attention because their physico-chemical properties are
different from the natural cyclodextrins.

However, the practical

application of modified cyclodextrins will have to await the results of
exhaustive toxicological studies.
Although a number of drug-cyclodextrin inclusion compounds are
reported in the literature at the laboratory level, little attention
appears to have been given to producing these products at the pil ot scale
or manufacturing level.

The results reported in this thesis clearly

demonstrate that inclusion compounds not only can be produced at the
pilot scale but also can be conveniently incorporated at a large scale
into pharmaceutically acceptable dosage forms .
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Appendix A, 1
Precision of HPLC assa_y_method for amg_icill in
Drug concentration

No of injections

Peak height

RSD( %)*

Xl0 3M

2.55

3

25200
25153

2. 15

24250
2.52

19645
20330

1.86

20248
2.58

6

24786
24858
24564

0. 74

24773
24839
24396

* Relative Standard Deviation

=

S. O. x 100
Mean

**A guideline for methods validation in New Drug Applications (NOA ) was
followed in this analytical work.
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Appendix A, 1 (contd).

Accurac_r_ of HPLC assay method for ampici 11 in
Amount added
(mg.)

Amount found

Recovery

(%)

(mg.)

~----- - ---- - ----- - --------------------------------------------- - --- - ---

1.003

1.012

100.90

0.802

0. 772

96 . 17

0.602

0.591

98.12

0.401

0.410

102.30

0.201

0.203

101. 20

Mean
Standard deviation

99.74

=

2. 52
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Appendix A, 2
Precision of HPLC ass'!.l_method for phenobarbitone
Drug concentration

No of injections

Peak height

RSD (%)

x 10-lM

1. 72

6

20860
20796
21388

1.69

20842
21426
21600
0.43

6

5620
5386
5410
5557
5494
5532

1.60
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Appendix A, 2 (contd).
Accuracy of HPLC assa..l'._rnethod for phenobarbitone
Amou nt added

Amount found

Recovery

(ucg)

(ucg)

(:t)

300

300.56

100 . 19

300

300 . 20

100.06

300

299.65

99.88

100

98. 70

98.70

100

99.00

99.00

100

98.30

98.30

40

38 . 88

97 . 20

40

38 . 10

95 . 25

40

38.40

96.00

Mean

=

Standard deviation

98.29
1. 77
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Appendix A, 3
Pecision of spectophotometric assay method for phenytoin
Drug concentration

UV Absorbance

RSD {%)

x 10 5M

1.60

0.206
0.224
0.218

3.93

0.210
0.229
0.216
3.17

0.763
0.738
0.747
0.768
0.750
0.749

1. 47
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Appendix A, 3 (contd) .
Accuracy of spectrophotometric assay method for pher:I.toin
Amount added

Amount found

Recovery

(ucg)

(ucg)

('.t)

4

3.78

94.50

4

3.85

96.25

4

3.90

97.50

8

7. 94

99.25

8

7.80

97.50

8

7.91

98.88

Mean

=

Standard devivation

97 . 31
1. 75
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Appendix A, 4
Molar

absorptivi~

(- ) of beta - cyclodextrin in pH 7.0 buffer

Co ncentration of beta-cyclodextrin

at225nm

3
x10 M

1.25
2.50
5. 00

7.15

10 . 00
15 . 00

* Since the molar absorptivity of phenytoin (10191 ) was more than
1000-fold compare to beta - cyclodextrin , hence it was felt that
interference of beta-cyclodextrin may be insignificant .
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Appendix B, 1
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Appendix B, 2
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